Novel Anti-L1cam Antibody

The application claims the priority of Chinese application 202111296133.4 filed on Nov. 3, 2021 and Chinese application 202210022509.0 filed on Jan. 10, 2022, the entire contents of which are incorporated herein by reference.

The invention relates to the field of biotechnology, and in particular relates to fully human monoclonal antibodies, antigen-binding fragments and chimeric antigen receptors specifically binding to human L1CAM, and nucleic acids required for constructing the antibodies, antigen-binding fragments and chimeric antigen receptors, plasmids, host cells, corresponding pharmaceutical compositions and applications thereof.

L1 cell adhesion molecule (L1 cell adhesion molecule), also known as CD171, is a transmembrane glycoprotein with a molecular weight between 200,000 and 220,000 [Miriam van der Maten et al., Int. J. Mol. Sci., 2019, 20:4180]. The expression of L1 cell adhesion molecules in healthy people is mainly limited to the nervous system, with a small amount of expression in kidney tissue and skin [Annette Kunkele et al., Clin. Cancer Res., 2016, 23:466-477]. L1 cell adhesion molecule has a high expression level in various tumors, and is closely related to the proliferation and drug resistance of various tumor cells.

L1 cell adhesion molecule is a potential tumor therapeutic target, but there is still a need for a therapeutic antibody against L1 cell adhesion molecule.

The inventors of the present invention obtained an anti-L1CAM monoclonal antibody with high specificity, high affinity and high stability by using hybridoma technology through screening.

In a first aspect, the present invention provides a L1CAM binding molecule comprising a fully human immunoglobulin that specifically binds L1CAM.

In another aspect, the present invention relates to nucleic acid molecules encoding L1CAM binding molecules and expression vectors and host cells containing said nucleic acid molecules.

In addition, the present invention also discloses nucleic acids encoding these fully cloned antibodies and antigen-binding fragments. In some embodiments, vectors comprising these nucleic acids, and host cells comprising these vectors are disclosed. In further embodiments, pharmaceutical compositions comprising these fully clonal antibodies, antigen-binding fragments, bispecific antibodies, immunoconjugates, fusion proteins, nucleic acids, and carriers are disclosed. In other embodiments, these fully cloned antibodies, antigen-binding fragments, bispecific antibodies, immunoconjugates, fusion proteins, nucleic acids, and vectors are used to diagnose or treat autoimmune diseases, chronic viral infections, and tumors.

The present invention discloses a novel fully human monoclonal antibody specific to L1CAM. By using this antibody CDR region or part or whole gene, different forms of genetically engineered antibodies can be modified and produced in prokaryotic and eukaryotic cells and any expression system, which can be used for clinical diagnosis or treatment of autoimmune diseases, chronic viral infections and tumors, etc. disease.

The present invention discloses a fully human monoclonal antibody specifically binding to human L1CAM, and the CDR region of the variable region of the light chain and/or the variable region of the heavy chain. In some embodiments, the amino acid sequence of the light chain variable region and/or the amino acid sequence of the heavy chain variable region of the monoclonal antibody or antigen-binding fragment comprises at least one CDR region of the light chain and/or heavy chain variable region. The present invention also discloses antigen-binding fragments of these monoclonal antibodies, bispecific antibodies, chimeric antigen receptor CARs, antibody conjugates, corresponding nucleic acids, plasmids and host cells, corresponding pharmaceutical compositions, and cancer use in diagnosis and treatment.

The present invention provides an antibody or antigen binding fragment thereof specifically binding to L1CAM comprising a light chain variable region comprising light chain complementarity determining regions LCDR1, LCDR2 and LCDR3 and/or a heavy chain variable region comprising heavy chain complementarity determining regions HCDR1, HCDR2 and HCDR3, wherein the antibody or antigen binding fragment thereof can specifically bind to the Ig1 or FN-4 domain of L1-CAM and does not have the same or equivalent combination of CDRs as antibody L1-9.3 or UJ127.

In one embodiment, wherein the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 comprising at least 80%, 90% or 100% identity to the HCDR1, HCDR2 and HCDR3 of the heavy chain variable region sequences selected from the group comprising SEQ ID NOs: 43, 45, 47, 49 and 51, and the light chain variable region comprises LCDR1, LCDR2 and LCDR3 comprising at least 80% identity to the LCDR1, LCDR2 and LCDR3 of the light chain variable region sequences selected from the group comprising SEQ ID NOs: 44, 46, 48, 50 and 52.

(1) HCDR1, HCDR2 and HCDR3 comprising at least 80% identity to HCDR1, HCDR2 and HCDR3 of the heavy chain variable region sequence of SEQ ID NO: 43, LCDR1, LCDR2 and LCDR3 comprising at least 80% identity to LCDR1, LCDR2 and LCDR3 of the light chain variable region sequence of SEQ ID NO: 44; (2) HCDR1, HCDR2 and HCDR3 comprising at least 80% identity to HCDR1, HCDR2 and HCDR3 of the heavy chain variable region sequence of SEQ ID NO: 45, LCDR1, LCDR2 and LCDR3 comprising at least 80% identity to LCDR1, LCDR2 and LCDR3 of the light chain variable region sequence of SEQ ID NO: 46; (3) HCDR1, HCDR2 and HCDR3 comprising at least 80% identity to HCDR1, HCDR2 and HCDR3 of the heavy chain variable region sequence of SEQ ID NO: 47, LCDR1, LCDR2 and LCDR3 comprising at least 80% identity to LCDR1, LCDR2 and LCDR3 of the light chain variable region sequence of SEQ ID NO: 48; (4) HCDR1, HCDR2 and HCDR3 comprising at least 80% identity to HCDR1, HCDR2 and HCDR3 of the heavy chain variable region sequence of SEQ ID NO: 49, LCDR1, LCDR2 and LCDR3 comprising at least 80% identity to LCDR1, LCDR2 and LCDR3 of the light chain variable region sequence of SEQ ID NO: 50; And (5) HCDR1, HCDR2 and HCDR3 comprising at least 80% identity to HCDR1, HCDR2 and HCDR3 of the heavy chain variable region sequence of SEQ ID NO: 51, LCDR1, LCDR2 and LCDR3 comprising at least 80% identity to LCDR1, LCDR2 and LCDR3 of the light chain variable region sequence of SEQ ID NO: 52. In one embodiment, wherein comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region and the light chain variable region have a combination of CDRs selected from the group comprising of:

(1) the HCDR1 comprises at least 80% identity to a sequence selected from SEQ ID NO: 1, SEQ ID NO: 7, SEQ ID NO: 13, SEQ ID NO: 19, SEQ ID NO: 25, SEQ ID NO: 31, SEQ ID NO: 37; (2) the HCDR2 comprises at least 80% identity to a sequence selected from SEQ ID NO: 2, SEQ ID NO: 8, SEQ ID NO: 14, SEQ ID NO: 20, SEQ ID NO: 26, SEQ ID NO: 32, SEQ ID NO: 38; (3) the HCDR3 comprises at least 80% identity to a sequence selected from SEQ ID NO: 3, SEQ ID NO: 9, SEQ ID NO: 15, SEQ ID NO: 21, SEQ ID NO: 27, SEQ ID NO: 33, SEQ ID NO: 39; (4) the LCDR1 comprises at least 80% identity to a sequence selected from SEQ ID NO: 4, SEQ ID NO: 10, SEQ ID NO: 16, SEQ ID NO: 22, SEQ ID NO: 28, SEQ ID NO: 34, SEQ ID NO: 40; (5) the LCDR2 comprises at least 80% identity to a sequence selected from SEQ ID NO: 5, SEQ ID NO: 11, SEQ ID NO: 17, SEQ ID NO: 23, SEQ ID NO: 29, SEQ ID NO: 35, SEQ ID NO: 41; (6) the LCDR3 comprises at least 80% identity to a sequence selected from SEQ ID NO: 6, SEQ ID NO: 12, SEQ ID NO: 18, SEQ ID NO: 24, SEQ ID NO: 30, SEQ ID NO: 36, SEQ ID NO: 42. In one embodiment, wherein:

(1) the HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 1; (2) the HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 2; (3) the HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 3; (4) the LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 4; (5) the LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 5; (6) the LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 6. In one embodiment, wherein,

(1) the HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 7; (2) the HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 8; (3) the HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 9; (4) the LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 10; (5) the LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 11; (6) the LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 12. In one embodiment, wherein,

(1) the HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 13; (2) the HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 14; (3) the HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 15; (4) the LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 16; (5) the LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 17; (6) the LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 18 In one embodiment, wherein,

(1) the HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 19; (2) the HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 20; (3) the HCDR3 comprises an amino acid sequence as set forth in SEQ ID NO: 21; (4) the LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 22; (5) the LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 23; (6) the LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 24 In one embodiment, wherein,

(1) the HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 25; (2) the HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 26; (3) the HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 27; (4) the LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 28; (5) the LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 29; (6) the LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 30 In one embodiment, wherein,

(1) the HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 31; (2) the HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 32; (3) the HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 33; (4) the LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 34; (5) the LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 35; (6) the LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 36 In one embodiment, wherein,

(1) the HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 37; (2) the HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 38; (3) the HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 39; (4) the LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 40; (5) the LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 41; (6) the LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 42 In one embodiment, wherein,

In one embodiment, wherein, the heavy chain variable region comprises an amino acid sequence comprising at least 90%, at least 95%, or 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 43 or to SEQ ID NO: 43.

In one embodiment, wherein, the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 44 or an amino acid sequence comprising at least 90%, at least 95%, or 100% sequence identity to SEQ ID NO: 44.

In one embodiment, wherein, the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 45 or an amino acid sequence comprising at least 90%, at least 95% or more sequence identity to SEQ ID NO: 45.

In one embodiment, wherein, the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 46 or an amino acid sequence comprising at least 90%, at least 95% or more sequence identity to SEQ ID NO: 46.

In one embodiment, wherein, the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 47 or an amino acid sequence comprising at least 90%, at least 95% or more sequence identity to SEQ ID NO: 47.

In one embodiment, wherein, the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 48 or an amino acid sequence comprising at least 90%, at least 95% or more sequence identity to SEQ ID NO: 48.

In one embodiment, wherein, the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 49 or an amino acid sequence comprising at least 90%, at least 95% or more sequence identity to SEQ ID NO: 49.

In one embodiment, wherein, the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 50 or an amino acid sequence comprising at least 90%, at least 95% or more sequence identity to SEQ ID NO: 50.

In one embodiment, wherein, the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 51 or an amino acid sequence comprising at least 90%, at least 95% or more sequence identity to SEQ ID NO: 51.

In one embodiment, wherein, the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 52 or an amino acid sequence comprising at least 90%, at least 95% or more sequence identity to SEQ ID NO: 52.

In one embodiment, wherein, the antibody is a humanized antibody.

The present invention provides an antibody or antigen-binding fragment, wherein, comprising a heavy chain variable region and/or a light chain variable region, wherein the heavy chain variable region comprises one of the amino acid sequences set forth in SEQ ID NO: 53 or SEQ ID NO: 54 or SEQ ID NO: 55 or SEQ ID NO: 56, and the light chain variable region comprises one of the amino acid sequences set forth in SEQ ID NO: 57 or SEQ ID NO: 58 or SEQ ID NO: 59.

1) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 53, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 57; or 2) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 53, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 58; or 3) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 53, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 59; or 4) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 54, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 57; or 5) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 54, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 58; or 6) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 54, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 59; or 7) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 55, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 57; or 8) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 55, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 58; or 9) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 55, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO 59; or 10) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 56, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 57; or 11) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 56, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 58; or 12) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 56, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 59. The present invention provides an antibody or antigen-binding fragment, wherein, comprises a heavy chain variable region and/or a light chain variable region, wherein:

In one embodiment, wherein, the heavy chain variable region comprises one of the amino acid sequences set forth in SEQ ID NO: 60 or SEQ ID NO: 61 or SEQ ID NO: 62 or SEQ ID NO: 63, and the light chain variable region comprises one of the amino acid sequences set forth in SEQ ID NO: 64 or SEQ ID NO: 65 or SEQ ID NO: 66.

1) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 60, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 64; or 2) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 60, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 65; or 3) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 60, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 66; or 4) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 61, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 64; or 5) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 61, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 65; or 6) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 61, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 66; or 7) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 62, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 64; or 8) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 62, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 65; or 9) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 62, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 66; or 10) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 63, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 64; or 11) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 63, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 65; or 12) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 63, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 66. In one embodiment, wherein, comprising a heavy chain variable region and/or a light chain variable region, wherein,

In one embodiment, wherein, the heavy chain variable region comprises one of the amino acid sequences set forth in SEQ ID NO: 67 or SEQ ID NO: 68 or SEQ ID NO: 69 or SEQ ID NO: 70 or SEQ ID NO: 71 or SEQ ID NO: 72 or SEQ ID NO: 73 or SEQ ID NO: 74 and the light chain variable region comprises one of the amino acid sequences set forth in SEQ ID NO: 75 or SEQ ID NO: 76 or SEQ ID NO: 77 or SEQ ID NO: 78 or SEQ ID NO: 79 or SEQ ID NO: 80 or SEQ ID NO: 81.

1) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 67, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 75; Or 2) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 67, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 76; Or 3) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 67, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 77; Or 4) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 67, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 78; Or 5) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 67 and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 79; Or 6) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 67, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 80; Or 7) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 67, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 81; Or 8) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 68 and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 75; Or 9) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 68, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 76; Or 10) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 68, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 77; Or 11) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 68, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 78; Or 12) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 68, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 79; Or 13) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 68, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 80; Or 14) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 68, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 81; Or 15) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 69, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 75; Or 16) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 69, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 76; Or 17) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 69, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 77; Or 18) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 69, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 78; Or 19) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 69, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 79; Or 20) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 69, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 80; Or 21) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 69, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 81; Or 22) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 70, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 75; Or 23) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 70, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 76; Or 24) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 70, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 77; Or 25) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 70, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 78; Or 26) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 70, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 79; Or 27) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 70, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 80; Or 28) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 70, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 81; Or 29) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 71, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 75; Or 30) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 71, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 76; Or 31) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 71, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 77; Or 32) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 71, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 78; Or 33) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 71, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 79; Or 34) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 71, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 80; Or 35) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 71, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 81; Or 36) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 72, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 75; Or 37) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 72, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 76; Or 38) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 72 and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 77; Or 39) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 72, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 78; Or 40) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 72, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 79; Or 41) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 72, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 80; Or 42) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 72, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 81; Or 43) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 73, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 75; Or 44) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 73, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 76; Or 45) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 73, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 77; Or 46) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 73, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 78; Or 47) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 73, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 79; Or 48) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 73, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 80; Or 49) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 73, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 81; Or 50) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 74, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 75; Or 51) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 74, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 76; Or 52) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 74, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 77; Or 53) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 74, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 78; Or 54) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 74, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 79; Or 55) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 74, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 80; Or 56) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 74, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 81. In one embodiment, wherein, comprising a heavy chain variable region and/or a light chain variable region, wherein,

In one embodiment, wherein, the heavy chain variable region comprises one of the amino acid sequences set forth in SEQ ID NO: 82 or SEQ ID NO: 83 or SEQ ID NO: 84 or SEQ ID NO: 85 or SEQ ID NO: 86 or SEQ ID NO: 87 or SEQ ID NO: 88 or SEQ ID NO: 89 or SEQ ID NO: 90, and the light chain variable region comprises one of the amino acid sequences set forth in SEQ ID NO: 91 or SEQ ID NO: 92 or SEQ ID NO: 93 or SEQ ID NO: 94 or SEQ ID NO: 95 or SEQ ID NO: 96.

1) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 82, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 91; Or 2) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 82, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 92; Or 3) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 82, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 93; Or 4) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 82, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 94; Or 5) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 82, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 95; Or 6) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 82, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 96; Or 7) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 83, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 91; Or 8) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 83, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 92; Or 9) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 83, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 93; Or 10) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 83, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 94; Or 11) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 83, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 95; Or 12) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 83, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 96; Or 13) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 84, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 91; Or 14) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 84, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 92; Or 15) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 84, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 93; Or 16) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 84, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 94; Or 17) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 84, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 95; Or 18) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 84, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 96; Or 19) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 85, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 91; Or 20) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 85, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO 92; Or 21) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 85, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 93; Or 22) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 85, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 94; Or 23) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 85, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 95; Or 24) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 85, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 96; Or 25) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 86, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 91; Or 26) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 86, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 92; Or 27) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 86, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 93; Or 28) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 86, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 94; Or 29) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 86, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 95; Or 30) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 86, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 96; Or 31) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 87, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 91; Or 32) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 87, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 92; Or 33) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 87, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 93; Or 34) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 87, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 94; Or 35) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 87, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 95; Or 36) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 87, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 96; Or 37) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 88, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 91; Or 38) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 88, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 92; Or 39) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 88, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 93; Or 40) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 88, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 94; Or 41) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 88, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 95; Or 42) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 88, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 96; Or 43) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 89, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 91; Or 44) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 89, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 92; Or 45) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 89, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 93; Or 46) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 89, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 94; Or 47) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 89, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 95; Or 48) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 89, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 96; Or 49) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 90, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 91; Or 50) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 90, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 92; Or 51) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 90, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 93; Or 52) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 90, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 94; Or 53) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 90, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 95; Or 54) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 90, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 96. In one embodiment, wherein, comprises a heavy chain variable region and/or a light chain variable region, wherein,

In addition, the present invention provides a fully humanized antibody or antigen-binding fragment, wherein, further comprising an Fc region, optionally that of a human immunoglobulin (Ig), or optionally that of a human IgG, whereas the Fc region is derived from human IgG1, IgG2, IgG3, IgG4, IgA1, IgA2 or IgM

2 2 The antigen-binding fragment in the present invention is scFv, scFv-Fc, Fv, Fab, Fab′, F (ab)or F (ab′).

2 Optionally, the antigen-binding fragment in the present invention is F (ab), Fab or scFv.

2 F(ab)fragments are “bivalent”. “Bivalent” means that the antibodies and F(ab′)2 fragments have two antigen combining sites. In contrast, Fab, Fv, and scFv fragments are monovalent, comprising only one antigen-binding site.

2 F(ab)is an antibody fragment comprising a molecular weight of about 50,000 and comprising antigen-binding activity among fragments obtained by treating an IgG antibody molecule with the protease papain (cleaving the amino acid residue at position 224 of the H chain), wherein about half of the N-terminal fragment and the entire L chain are held together by disulfide bonds (C. A. K Borrebaeck, editor (1995) Antibody Engineering (Breakthroughs in Molecular Biology), Oxford University Press; R. Kontermann & S. Duebel, editors (2001) Antibody Engineering (Springer Laboratory Manual), Springer Verlag).

2 2 Fab is an antibody fragment comprising a molecular weight of about 50,000 and comprising antigen-binding activity obtained by cleaving the disulfide bond in the hinge region of the above-mentioned F(ab′). The Fab of the invention can be produced by treating F(ab)with a reducing agent such as dithiothreitol.

“Single-chain Fv” or “scFv” means a molecule comprising an antibody heavy chain variable domain (or region; VH) and an antibody light chain variable domain (or region; VL) connected by a linker. Such scFv molecules may comprise the general structure: H2-VL-linker-VH-COOH or H2-VH-linker-VL-COOH. Suitable prior art linkers consist of the repeated GGGGS amino acid sequence or variants thereof, for example using 1-4 repeat variants.

The antibody or antigen-binding fragment in the present invention is a monoclonal antibody, a bispecific antibody, a multispecific antibody, a recombinant antibody, a chimeric antibody, a divalent antibody, an anti-idiotypic antibody, or a fusion protein.

Besides, the present invention also provides an antibody-drug conjugate comprising the aforementioned antibody or antigen-binding fragment, and an additional effector molecule conjugate.

Besides, the present invention also provides a nucleic acid molecule encoding the aforementioned antibody or antigen-binding fragment.

The nucleic acid molecule of the present invention, a promoter is operably linked.

In addition, the present invention also provides a recombinant expression vector, which comprises the aforementioned nucleic acid molecule of the present invention.

In addition, the present invention also provides a plasmid containing the nucleic acid molecule of the present invention.

In addition, the present invention also provides a host cell containing the nucleic acid molecule of the present invention, the recombinant expression vector of the present invention or the plasmid of the present invention.

In addition, the present invention also provides a method for detecting L1CAM expression in a biological sample, comprising the following steps: contacting the biological sample with any of the aforementioned antibodies or antigen-binding fragments thereof of the present invention, and detecting the expression of the immune The presence or absence of the complex, wherein the presence of the immune complex indicates the presence of L1CAM in the biological sample.

In addition, the present invention also provides a pharmaceutical composition, including any antibody or antigen-binding fragment thereof of the present invention. The antibody-drug conjugate of the present invention act as an active substance, and a pharmaceutically acceptable carrier.

The present invention provides a pharmaceutical composition, an antibody or antigen-binding fragment or bispecific antibody or chimeric antigen receptor of the present invention or a nucleic acid molecule thereof, a plasmid or a cell expressing the chimeric antigen receptor, and physiologically or pharmaceutically acceptable carrier, excipient or stabilizer. The composition includes but not limited to freeze-dried dosage form, aqueous solution dosage form, liposome or capsule, etc. The concentration of the monoclonal antibody or antigen-binding fragment or bispecific antibody or chimeric antigen receptor or nucleic acid molecule thereof, plasmid or cell expressing the chimeric antigen receptor of the invention can vary from about 0.1% to 100% (weight).

In addition, the present invention also provides a kit, including any one of the aforementioned antibodies or antigen-binding fragments of the present invention, the antibody-drug conjugates described in the present invention and/or the antibody-drug conjugates described in the present invention pharmaceutical composition.

In addition, the present invention also provides a method for treating cancer, which includes administering any one of the aforementioned antibodies or antigen-binding fragments thereof, the antibody-drug conjugates described in the present invention to a subject in need thereof, or the pharmaceutical composition of the present invention.

In the aforementioned method of the present invention, it also includes detecting the presence of L1-CAM in the cancer sample before administering the drug.

Preferably, the antibodies or antigen-binding fragments of the present invention are fully humanized. The said fully humanized is an antibody or an antigen-binding fragment thereof is defined herein is non-chimeric (e.g., non-humanized) and does not come from non-humanized species (whether the whole is still part). fully human antibody or antigen-binding fragment thereof can be derived from human, or can be synthetic human antibody. Another example of a fully human antibody or an antigen-binding fragment thereof is a human antibody encoded by nucleic acid isolated from a library of antibody sequences of human origin (e.g., based on such a library of antibodies taken from natural sources of humans).

The antibody or antigen-binding fragment thereof of the invention, which is a monoclonal antibody, bispecific antibody, multi-specific antibody, recombinant antibody, chimeric antibody, divalent antibody, anti-idiotypic antibody or fusion protein.

The invention also provides an antibody or antigen binding fragment capable of binding L1CAM, which is a bispecific antibody or a bispecific antigen-binding fragment. In some embodiments, the bispecific antibody or bispecific antigen-binding fragment may be isolated. The term “bispecific” means that the antigen-binding molecule is capable of specifically binding to at least two different antigenic determinants. The bispecific antibodies and bispecific antigen-binding fragments comprise an antigen-binding fragment according to the present invention. In some embodiments, the bispecific antibodies and bispecific antigen binding fragments comprise an antigen binding fragment capable of binding to L1CAM, wherein the antigen binding fragment capable of binding to L1CAM comprises an antigen binding fragment according to the present invention. In some embodiments, the bispecific antibodies and bispecific antigen binding fragments comprise an antigen binding fragment capable of binding to L1CAM, and an antigen binding fragment capable of binding to another target protein. In some embodiments, the bispecific antibody or antigen-binding fragment comprises an antigen-binding molecule capable of binding L1CAM and an antigen-binding molecule capable of binding other than L1CAM. The antigen other than L1CAM is an immune cell surface molecule. In some embodiments, the antigen other than L1CAM is a cancer cell antigen In some embodiments, the antigen other than L1CAM is a receptor molecule, e.g., a cell surface receptor.

Escherichia coli, Bacillus subtilis The present invention provides a nucleic acid encoding said monoclonal antibody or antigen-binding fragment or bispecific antibody or chimeric antigen receptor. The present invention provides a plasmid comprising the nucleic acid, optionally operably linked to regulatory sequences such as promoters, enhancers and the like. The invention provides host cells comprising the plasmid, and methods for producing and optionally recovering the monoclonal antibody or antigen-binding fragment or bispecific antibody or chimeric antigen receptor. The host cell of the present invention can be any prokaryotic cell or eukaryotic cell, including but not limited to bacterial cells (such as), insect cells (such as using a baculovirus expression system), yeast or mammalian cells (such as CHO or BHK cell lines). Other suitable host cells are known to those skilled in the art.

Preferably, the disease described in the present invention is cancer, including but not limited to lymphoma, blastoma, sarcoma (including liposarcoma), neuroendocrine tumor, mesothelioma, schwannoma, meningioma, adenoma, melanoma and nonleukemic leukemia or lymphoid malignancies. More specific examples of the aforementioned cancers include squamous cell carcinoma (e.g., squamous cell carcinoma), lung cancer, small cell lung cancer, non-small cell lung cancer, lung adenocarcinoma, and lung squamous cell carcinoma, peritoneal carcinoma, hepatocellular carcinoma, gastric cancer, gastrointestinal cancer, pancreatic cancer, malignant glioma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, rectal cancer, colorectal cancer, endometrial or uterine cancer, salivary gland cancer, kidney cancer, prostate cancer, vulvar cancer, thyroid cancer, liver cancer, anal cancer, penis cancer, testicular cancer, esophagus cancer, bile duct tumor, head cancer, neck cancer, bone marrow stromal tumor, osteoclastoma, multiple myeloma, Osteolytic bone cancers, central nervous system tumors, brain tumors (glioma, neuroblastoma, astrocytoma, medulloblastoma, ependymoma, and retinoblastoma), nasopharyngeal carcinoma, basal cell carcinoma, cholangiocarcinoma, Kaposi's sarcoma, primary liver or endometrial carcinoma, and tumors of the vasculature (angiosarcoma and hemangiopericytoma), hematologic neoplasms, Hodgkin's lymphoma, non-Hodgkin's lymphoma (Burkitt's lymphoma, small lymphocytic lymphoma/chronic lymphocytic leukemia, mycosis fungoides, mantle cell lymphoma, follicular lymphoma, diffuse giant B-cell lymphoma, marginal zone lymphoma, hairy cell leukemia, and lymphoplasmacytic leukemia), lymphocyte precursor cell neoplasms, B-cell acute lymphoblastic nonleukemic leukemia/lymphoma, T-cell acute Lymphoblastic nonleukemic leukemia/lymphoma, thymoma, mature T and NK cell neoplasms, peripheral T cell nonleukemic leukemia, mature T cell nonleukemic leukemia/T cell lymphoma, large granular lymphocytic leukemia, Langerhans cell histiocytosis, myeloma in acute myeloid leukemia, mature acute myeloid leukemia (AML), differentiated acute myeloid leukemia, acute promyelocytic leukemia, acute myelomonocytic leukemia, acute monocytic leukemia, myelodysplastic syndrome, chronic myeloproliferative disease, chronic myelogenous leukemia, hematologic malignancies such as multiple myeloma (MM), myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).

The antibodies or antigen-binding fragments or bispecific antibodies or chimeric antigen receptors or nucleic acid molecules thereof, plasmids or cells expressing the chimeric antigen receptors of the present invention, and pharmaceutical compositions can be administered through various routes For human or animal subjects, the route of administration generally depends on the characteristics of the disease to be treated itself. In general, the methods of the present invention may be practiced using any mode of administration that is medically acceptable, including oral, rectal, topical, intraocular, intracisternal, intracerebroventricular, intratracheal, intranasal drops injection, transdermal, subcutaneous, intrathecal, intramuscular, intraperitoneal, intraperitoneal, intracranial infusion or intravenous infusion.

In order that the invention may be more thoroughly understood, some definitions are listed below. The above definitions are intended to include grammatical equivalents.

As used herein, “antibody” refers to a protein consisting of one or more polypeptides encoded by substantially all or part of a recognized immunoglobulin gene. the recognized immunoglobulin gene, such as in a human, comprising kappa (κ), lambda (lambda) and a heavy chain locus, wherein comprising a plurality of variable region gene, and the isotype constant region gene mu (μ) delta (delta), gamma (gamma), epsilon (epsilon), alpha (alpha) respectively encoding IgM, IgD, IgG, IgE and IgA. Antibodies herein are meant to include full-length antibodies and antibody fragments, as well as natural antibodies from any organism, engineered antibodies, or recombinantly produced antibodies for experimental, therapeutic or other purposes as further specified below. The term “antibody” includes antibody fragments, known in the art, such as Fab, Fab′, F(ab′)2, Fv, scFv, or other antigen-binding subsequences of antibodies, or by modifying intact antibodies or using recombinant DNA techniques Antibody fragments produced by de novo synthesis of those antibodies. The term “antibody” includes monoclonal as well as polyclonal antibodies. Antibodies can be antagonists, agonists, neutralizing antibodies, or inhibitory antibodies, or stimulating antibodies. Antibodies of the invention may be non-human antibodies, chimeric antibodies, humanized antibodies or fully human antibodies.

The term “monoclonal antibody” as used herein refers to an antibody that is obtained from a substantially homogeneous antibody population, i.e., the population comprising a single antibody may be the same in addition to possible mutations (e.g., natural mutations) that may be present in a very small amount. Thus, the term “monoclonal” indicates the nature of the antibody, i.e., not a mixture of non-related (discrete) antibodies. In contrast to the polyclonal antibody preparations that typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody of the monoclonal antibody formulation is directed against a single determinant on the antigen. In addition to their specificity, monoclonal antibody preparations are advantageous in that they are not normally contaminated by other immunoglobulins. The term “monoclonal” should not be understood to require the production of the antibodies by any particular method. The term monoclonal antibody specifically comprises a fully human antibody. (refCN201280062865-antibody of anti-FGFR2 and application-adjudication grant)

As used herein, the term “complementarity determining region” (CDR, e.g., CDR1, CDR2, and CDR3) refers to an amino acid residue of an antibody variable region, and the presence of complementarity determining regions is necessary for antigen binding. The “antigen-binding region” of the antibody is usually present in one or more hypervariable regions of the antibody, for example, CDR regions of CDR1, CDR2 and CDR3. each complementarity determining region may comprise amino acid residues from the complementarity determining region as defined by Kabat, for example, residues 24-34 (L1), 50-56 (L2) and 89-97 (L3) in the light chain variable region and 26-33 (H1) in the heavy chain variable region, 51-57 (H2) and 96-105 (H3) (Kabat et al, Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, 1991).

“Antigen” as used herein means a compound, composition or substance that can stimulate antibody production or T cell response in an animal, including compositions injected or absorbed into the animal, which can be a protein, carbohydrate, lipid or other Pathogens.

The “functional fragment” or “antigen-binding fragment” of an antibody/immunoglobulin is defined herein as a fragment of an antibody/immunoglobulin that retains the antigen-binding region (e.g., a variable region of IgG). The “antigen-binding region” of the antibody is usually present in one or more hypervariable regions of the antibody, e.g., CDR1, CDR-2 and/or CDR-3 regions; However, the variable “framework” region may also play an important role in antigen binding, for example, by providing a framework for a CDR. Preferably, the antigen-binding region comprises at least amino acid residue of variable light (VL) 4-103 and amino acid residue of variable heavy (VH) chain 5-109 5-109, more preferably VL amino acid residue 3-107 and VH of amino acid residue 4-111; and particularly preferably a complete VL and VH chain (VL amino acid first 1-109 and VH amino acid position 1-113); No. WO 97/08320). A preferred class of immunoglobulins for use in the present invention are IgG.

As used herein, “amino acid” means one or any non-natural analog of 20 naturally occurring amino acids, which may be located at a specific specified position. The term “protein” refers to at least two covalently linked amino acids, which include proteins, polypeptides, oligopeptides and peptides. The protein can be composed of naturally occurring amino acid and peptide bond, or composed of synthetic peptide mimetic structure, the peptide mimetic is analogue. As such, “amino acid” or “peptide residue” as used herein means a naturally occurring and synthetic amino acid. For example, for purposes of the present invention, homophenylalanine, citrulline and norleucine are considered to be amino acids for the purposes of the present invention. “Amino acid” also includes a subamino acid residue such as proline and hydroxyproline. The side chain may be (R) or (S) configuration. In a preferred embodiment, the amino acid is present in the (S) or L-configuration. If a non-naturally occurring side chain is used, a non-amino acid substitution may be used, for example, to prevent or delay degradation in vivo.

As used herein, “Identity” means similarity between nucleotide or amino acid sequences, otherwise known as sequence identity. Sequence identity is usually measured in terms of percent identity (or similarity or homology); the higher the percent, the more similar the two sequences are. Homologs or variants will have a relatively high degree of sequence identity when aligned using standard methods. Sequence alignment methods for comparison are well known in the art. Various procedures and alignment algorithms are described in: Smith and Waterman, Adv Appl. Math., 2: 482, 1981; Needleman and Wunsch, J. Mol. Biol. 48: 443, 1970; Pearson and Lipman, Proc. Natl. Acad. Sci. U.S.A. 85:2444, 1988; Higgins and Sharp, Gene 73: 237-244, 1988; Higgins and Sharp, CABIOS 5: 151-153, 1989; Corpet et. al, Nucleic Acids Research 16: 10881-10890, 1988; and Altschul et. al, Nature Genet., 1994, 6: 119-129.

The NCBI Basic Local Alignment Search Tool (BLAST™) (Altschul et al., J. Mol. Biol., 215:403-410, 1990) is available from several sources, including the National Center for Biotechnology Information (NCBI, Bethesda, Md.) and are available on the Internet for the sequence analysis programs blastp, blastn, blastx, tblastn and tblastx.

As used herein, “nucleic acid” means a polymer formed by phosphodiester bond between nucleotide units (ribonucleotides, deoxyribonucleotides, related naturally occurring structural variants and synthetic non-naturally occurring analogs thereof). Thus, the term includes nucleotide polymers in which the nucleotides and the bonds between them include non-naturally occurring synthetic analogs such as, but not limited to, phosphorothioates, phosphoramidates, methyl phosphates, chiral Methyl phosphate, 2′-O-methylribonucleotide, peptide nucleic acid (PNA), etc. For example, these polynucleotides can be synthesized using an automated DNA synthesizer. The term “oligonucleotide” generally refers to short polynucleotides, usually no more than about 50 nucleotides. It will be understood that when a nucleotide sequence is represented by a DNA sequence (i.e. A, T, G, C), this also includes an RNA sequence in which “U” replaces “T” (i.e. A, U, G, C).

Conventional symbols are used herein to describe nucleotide sequences: the left-hand 5′ end of a single-stranded nucleotide sequence; the left-hand direction of a double-stranded nucleotide sequence is called the 5′ direction. The direction in which 5′ to 3′ nucleotides added to the nascent RNA transcript is called the direction of transcription. The DNA strand with the same sequence as the mRNA is called the coding strand.

As used herein, “encoding” refers to the intrinsic properties of specific nucleotide sequences in polynucleotides, such as genes, cDNA or mRNA, used as templates for the synthesis of other polymers and macromolecules in biological processes with defined nucleotide sequences, or defined amino acid sequences and resulting biological properties. Thus, if the transcription and translation of mRNA produced by that gene produces a protein in a cell or other biological system, the gene encodes for a protein. Coding strands (whose nucleotide sequence is identical to the mRNA sequence and are usually provided in the sequence list) and non-coding strands (used as transcription templates, genes, or cDNA) can be referred to as coding proteins. or other products of that gene or cDNA. Unless otherwise stated, “nucleotide sequences encoding amino acid sequences” includes all nucleotide sequences that are degenerate with each other and encode the same amino acid sequence. Nucleotide sequences encoding proteins and RNA may include introns.

As used herein, the “plasmid” used herein refers to a plasmid artificially constructed based on a natural plasmid to adapt to laboratory operations. Nucleic acid molecules can be introduced into a host cell, thereby producing a transformed host cell. The vector may include nucleic acid sequences that permit its replication in the host cell, such as an origin of replication, and may also include one or more selectable marker genes and other genetic elements known in the art.

The term “host cell” as used herein, also known as recipient cell, refers to a host cell that receives an exogenous gene in transformation and transduction (infection).

As used herein, “pharmaceutically acceptable carrier” means a conventional pharmaceutically acceptable vehicle. Remington's Pharmaceutical Sciences, E W Martin, Mack Publishing Co., Easton, Pa., 15th edition (1975), describing compositions and formulations suitable for drug delivery of one or more therapeutic compounds or molecules (e.g., one or more antibodies), and additional agents.

As used herein, the term “diagnostic” disease refers to the determination of the patient's condition and its development after examination of the patient. “Preventing” a disease means inhibiting the complete development of the disease. “Treatment” means a therapeutic intervention that improves the signs or symptoms of a disease or pathological condition after it begins to develop.

As used herein, “Administering” means selecting the appropriate route to introduce said substance into the subject. For example, if the chosen route is intravenous, the composition is administered by introducing said substance into the subject's vein.

As used herein, “effective preventive/therapeutic dose” means a specific agent sufficient to achieve the desired effect in subjects treated with this agent. The exact dose will depend on the purpose of treatment and may be determined by those skilled in the art through the use of well-known techniques. Doses range from 0.01 to 100 mg/kg body weight or larger, such as 0.1, 1, 10, or 50 mg/kg body weight, preferably 1-10 mg/kg. As well known in the art, for antibody or Fc fusion degradation, systemic or local drug delivery and rate of new protease synthesis, as well as age, weight, general health status, sex, diet, timing of administration, drug interactions, and severity of the condition, adjustments may be necessary and may be determined by those skilled in the art by conventional experimental methods. Such reagents include monomeric Fc domain molecules described herein. In a non-limiting instance, this can be the amount of HIV-specific monomer Fc domains (or HIV-specific CH3 domain molecules) used to prevent, treat, or improve HIV infection. Ideally, a therapeutically effective amount of antibody is an amount sufficient to prevent, treat, or improve infection or disease, such as caused by HIV infection in the subject, without causing a significant cytotoxic effect in the subject. The treatment-effective amount of the agent used for prevention, improvement and/or treatment of subjects will depend on the subject being treated, the type and severity of suffering, and the manner in which the therapeutic composition is administered.

As used herein, “cancer” is a solid tumor or a bloodborne cancer. The solid tumor described in the present invention is sarcoma or carcinoma, such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteosarcoma, or another sarcoma, synovioma, mesothelioma, Ewing tumor, leiomyosarcoma, rhabdomyosarcoma, colon cancer, lymphoid malignancy, pancreatic cancer, breast cancer, lung cancer, ovarian cancer, prostate cancer, hepatocellular carcinoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous adenocarcinoma, papillary carcinoma, papillary adenocarcinoma, medullary carcinoma, bronchial carcinoma, renal cell carcinoma, hepatocellular carcinoma, Cholangiocarcinoma, choriocarcinoma, Wilms tumor, cervical cancer, testicular tumor, bladder cancer, or central nervous system tumor (eg, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pineal gland, angioblastoma, acoustic neuroma, oligodendroglioma, hemangioma, melanoma, neuroblastoma, or retinoblastoma). The bloodborne cancer described in the present invention is leukemia, such as acute leukemia (such as acute lymphoblastic leukemia, acute myeloid leukemia, acute myeloid leukemia and myeloblasts, promyelocyte, myeloid monocytes, monocytes and erythrocyte); Chronic leukemia (e.g. chronic myelogenous (granulocytic) leukemia, chronic myeloid leukemia and chronic lymphocytic leukemia), polycythemia vera, lymphoma, Hodgkin's disease, non-Hodgkin lymphoma (indolent and advanced form), multiple myeloma, Waldenstrom macroglobulinemia, heavy chain diseases, myelodysplastic syndrome, hirsutistic leukemia or myelodysplastic disorders.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood the ordinary skilled person in the technical field. The singular terms “a”, “an” and “the” include plural referents unless the context clearly dictates otherwise. It is also to be understood that all base sizes or amino acid sizes, and all molecular weight or molecular weight values given for nucleic acids or polypeptides are approximate and are provided for purposes of description. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, suitable methods and materials are described below. The term “comprising” means “including”. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In the event of conflict, this specification (including explanation of terms) will control. In addition, the materials, methods, and examples are illustrative only and not limiting.

Unless otherwise defined, technical and scientific terms used herein have the same meaning as commonly understood by the skilled person in the art. Furthermore, the terms and laboratory procedures related to protein and nucleic acid chemistry, molecular biology, cell and tissue culture, microbiology, and immunology used in this article are terms and routine procedures widely used in the corresponding fields. Meanwhile, in order to better understand the present invention, definitions and explanations of relevant terms are provided below.

The term “L1CAM” as used herein refers to any variant, isoform and species homologue of L1CAM. L1CAM is a transmembrane glycoprotein with a molecular weight between 200,000 and 220,000, also known as CD171. Structurally, the extracellular part of L1CAM consists of six immunoglobulin-like domains and five type III fibronectin repeats starting from the amino terminus of the protein. In addition, L1CAM also contains a transmembrane domain and an intracellular domain. domain. In certain embodiments, the L1CAM is human L1CAM. Exemplary sequences of human L1CAM proteins are disclosed in NCBI Ref Seq No. NP_001265045.1, NCBI Ref Seq No. NP_000416.1, NCBI Ref Seq No. NP_076493.1, and NCBI Ref Seq No. NP_001137435.1. Exemplary predicted sequences for the monkey L1CAM protein are disclosed in NCBI Ref Seq No. XP_005594990.1, Ref Seq No. 1.

The term “antibody” as used herein refers to any immunoglobulin that binds to a specific antigen. A natural intact antibody contains two heavy (H) chains and two light (L) chains. Each heavy chain in mammals consists of a variable region (VH) and first, second, third and fourth (optionally) constant regions (CH1, CH2, CH3, CH4, respectively); mammalian light chains can be divided into lambda or kappa, and each light chain consists of a variable region (VL) and a constant region. The variable regions of the light and heavy chains determine antigen binding. The variable region of each chain usually contains three hypervariable regions, called complementarity determining regions (CDRs) (the light chain CDR includes LCDR1, LCDR2, and LCDR3, and the heavy chain CDR includes HCDR1, HCDR2, and HCDR3). The CDR boundaries of the antibodies and antigen-binding fragments disclosed in the present invention may be named or identified by Kabat nomenclature.

The term “monoclonal antibody” as used in the present invention refers to a population of identical antibodies, indicating that each individual antibody molecule in the monoclonal antibody population is the same as other antibody molecules. This characteristic is contrary to the characteristics of the polyclonal population of the antibody, the polyclonal population of the antibody comprises an antibody comprising a variety of different sequences.

The term “bispecific antibody” used in the present invention refers to an artificial antibody that has fragments derived from two different monoclonal antibodies and is capable of binding to two different epitopes. The two epitopes may be present on the same antigen, or they may be present on two different antigens.

The term “multispecific antibody” used in the present invention refers to an artificial antibody that has fragments derived from multiple different monoclonal antibodies and is capable of binding to multiple different epitopes. The multiple epitopes may be present on the same antigen, or they may be present on multiple different antigens.

The term “recombinant antibody” used in the present invention refers to antibodies produced by expression in engineered cell lines or engineering strains through recombinant genetic engineering technology.

The term “chimeric antibody” as used herein refers to an antibody molecule in which the antibody constant region or part thereof is replaced such that the antigen binding site (variable region, CDR or part thereof) is linked to the constant region of a different species.

2 The term “amino acid” as used in the present invention refers to organic compounds containing amino ((—NH) and carboxyl (—COOH) functional groups and side chains unique to each amino acid. Amino acid names are also used in the present invention in accordance with standards recognized in the art. represented by a one-letter or three-letter code.

“Treatment” or “therapy” for a disease, condition or condition as used in the present invention includes preventing or alleviating a disease, indication or condition, reducing the rate at which a disease, condition or condition occurs or develops, reducing the risk of developing a disease, indication or condition, preventing or delaying the development of symptoms associated with a disease, indication or condition, reducing or terminating symptoms associated with a disease, indication or condition, producing a complete or partial reversal of a disease, indication or condition, curing a disease, indication or condition, or a combination of those.

The term “diagnosis” as used herein refers to the identification of a pathological state, disease or condition, such as the identification of a cancer-related disease, or to the identification of a subject who may benefit from a particular treatment regimen.

The present invention will be further described by way of embodiment, but does not limit the present invention to the scope of the described embodiments.

To generate L1CAM antibodies, Balb/c mice were immunized with recombinantly expressed human L1CAM antigen fragments. During the immune operation, blood was collected from the mice regularly to obtain serum samples and monitor the immune response. Mice with sufficient titers of anti-L1CAM antibodies were used for fusion experiments. Splenocytes and/or lymph node cells from immunized mice were isolated and fused with mouse myeloma cell lines. By performing ELISA analysis with the recombinant protein of the extracellular domain of human L1CAM, hybridomas that can produce L1CAM-specific antibodies were screened out using HeLa cells that highly express human L1CAM and HEK293 cells that highly express monkey L1CAM, and were subcloned to obtain stable of hybridoma clones. After subcloning, the monoclonal hybridoma cells are subjected to antibody sequencing for further analytical testing.

In the present invention, the mouse anti-L1CAM monoclonal antibody is represented by “hybridoma clone number”. For example, the mouse anti-L1CAM monoclonal antibody derived from hybridoma clone 25F8H8 is represented by “25F8H8”.

Based on the results of monoclonal hybridoma cell antibody sequencing, human-mouse chimeric antibodies with CH1, CH2 and CH3 of human IgG1 as constant regions and VH and VL of murine anti-L1CAM monoclonal antibodies as variable regions were designed and recombinant expressed in mammalian cells and purified for further analysis and testing. In the present invention, the chimeric antibody number is indicated as “ch+ hybridoma clone number”, for example, a chimeric antibody from hybridoma clone 25F8H8 is indicated as “ch25F8H8”

6 HeLa cells used in this example were used to measure the binding of mouse anti-L1CAM monoclonal antibodies to endogenously expressed human L1CAM on the cell surface. HeLa cells were cultured in DMEM complete medium (purchased from Corning) containing 10% FBS (purchased from Gibco) and 100 U/mL penicillin-streptomycin mixture (Thermofisher, 15140122). When the coverage of the cells in the culture container reached to 80-90%, using TrypLE (purchased from Thermofisher) to digest Hela cells from the culture container, and seed them in a 96-well plate (purchased from AXYGEN) at a density of 4×10cells/ml, with 100,000 cells per well (25 μL DMEM complete culture medium), then add 25 μL of diluted hybridoma supernatant containing antibodies to each well, mix gently, and incubate the 96-well plate at 4° C. for 1 hour. Then add 150 μL of PBS buffer containing 2% FBS (purchased from Corning) to each well, centrifuge at 1400 rpm for 4 minutes, remove the supernatant, and repeat washing once. Then, 50 μL of 1:800 diluted Alexa Flour 647-labeled goat anti-mouse fluorescent secondary antibody (purchased from Jacksonimmuno) was added to each well, and the 96-well plate was incubated at 4° C. for 0.5 hours. The cells were washed twice with PBS solution containing 2% FBS, and then resuspended in 120 μL of PBS. The fluorescence signal on the cell surface was detected using a flow cytometer (BD FACSCelesta) to obtain the median fluorescence intensity (MFI). The antibody-containing hybridoma supernatant was assayed using an anti-mouse ELISA assay to determine the concentration of mouse IgG in the supernatant. Finally, a dose-response curve was generated, and the half effective concentration (EC50) was calculated by nonlinear regression using GraphPad software.

TABLE 1 The binding of mouse anti-L1CAM monoclonal antibody to HeLa cells Antibody NO. EC50 (nM) 25F8H8 0.1927 26A12C1 0.2414 46F1D5 0.144 49E10H1 0.2333 103E9B3 0.4356

This example utilizes HeLa cells and L1CAM-knockout HeLa cells (purchased from Abcam) to determine the binding of mouse anti-L1CAM monoclonal antibodies to endogenously expressed human L1CAM on the cell surface. L1CAM-knockout HeLa cells are referred to as HeLa KO cells in this invention.HeLa cells are cultured in DMEM complete medium (purchased from Corning) containing 10% FBS (purchased from Gibco) and 100 U/mL penicillin mixture (Thermofisher, 15140122). When the cell coverage in the culture container reaches 80-90%, TrypLE (purchased from Thermofisher) is used to digest the HeLa and HeLa KO cells from the culture container, and they are seeded in a 96-well plate (purchased from AXYGEN) at a density of 4×106 cells/ml, with 100,000 cells (25 μL DMEM complete medium) per well. Then, the human-mouse chimeric antibodies are serially diluted in DMEM complete medium, with 25 μL of the diluted chimeric antibody solution added to each well, gently mixed, and incubated at 4° C. for 1 hour. Then, 150 μL of PBS buffer containing 2% FBS (purchased from Corning) is added to each well, centrifuged at 1400 rpm for 4 minutes, the supernatant is removed, and the wells are washed once more. Then, 50 μL of Alexa Flour 647-labeled goat anti-human fluorescent secondary antibody (purchased from Jacksonimmuno) diluted 1:800 is added to each well, and the 96-well plate is incubated at 4° C. for 0.5 hours. The cells are washed twice with PBS solution containing 2% FBS, then resuspended in 120 μL of PBS, and the cell surface fluorescence signal is detected using a flow cytometer (BD FACSCelesta), obtaining the median fluorescence intensity (MFI). A dose-response curve is generated, and the half-maximal effective concentration (EC50) is calculated using non-linear regression with GraphPad software. HeLa cells endogenously express high levels of L1CAM, and the expression level of L1CAM in HeLa KO cells is significantly reduced relative to wild-type HeLa due to the knockout of the L1CAM gene, allowing the binding ability of antibodies to L1CAM on the surface of HeLa cells to be determined by flow cytometry, and the specificity of the antibodies is assessed by detecting the fluorescence signal on the surface of HeLa KO cells.

TABLE 2 The binding of anti-L1CAM human-mouse chimeric antibodies to HeLa cells and HeLa cells HelaCell Hela KO Cell chimeric Maxium Maxium antibodies NO. EC50(nM) MFI EC50(nM) MFI ch25F8H8 0.8331 29253 1.557 372 ch26A12C1 0.7392 44705 0.319 1165 ch46F1D5 0.8452 43085 0.4688 1739 ch49E10H1 0.9783 42858 0.3136 2640 ch103E9B3 1.113 45397 N/A N/A Note: N/A represents data not available

Mouse anti-L1CAM monoclonal antibodies 46F1D5, 49E10H1, and 103E9B3 are selected as clones for humanization. The antibody sequences are aligned with human germline sequences to determine the best fit model. Based on homology with the original mouse antibody sequences, the most matching human germline sequences are selected as templates for humanization. The CDRs from the mouse antibody sequences are grafted onto the template along with residues that preserve the upper and central core structures of the antibody. Optimized mutations are introduced into the framework region to produce variants of the humanized heavy chain variable region and the humanized light chain variable region, which are mixed and matched to provide multiple humanized antibody clones. They are recombinantly expressed in mammalian cells and purified for further analytical testing.

6 The experimental principle is as follows: HeLa cells express high levels of L1CAM protein on their surface. After incubating humanized L1CAM antibodies with the cells, the binding ability of the antibodies to L1CAM on the surface of HeLa cells can be determined by flow cytometry.The experimental method is descripted as following:Humanized L1CAM antibodies (Human IgG1-Kappa) are diluted in complete medium in a four-fold serial dilution, with seven concentration gradient points.HeLa cells are cultured in DMEM complete medium (Corning, 10-013-CVR) containing 10% FBS (Gibco, 10099-141) and 100 U/mL penicillin mixture (Thermofisher, 15140122). When the cell coverage in the culture container reaches 80-90%, TrypLE (Thermofisher, 12604-013) is used to digest the HeLa cells from the culture container, and they are seeded in a 96-well plate (AXYGEN, P-96-450V-C) at a density of 2.2×10cells/ml, with 100,000 cells (45 μL complete medium) per well. Then, 5 μL of the antibody dilution is added to each well, gently mixed, and the 96-well plate is incubated at 4° C. for 1 hour. Then, 150 μL of PBS solution containing 2% FBS (Corning, 21-040-CVC) is added to each well, centrifuged at 1400 rpm for 4 minutes, the supernatant is removed, and the wells are washed once more. Then, 50 μL of Alexa Flour 647-labeled goat anti-human fluorescent secondary antibody (Jacksonimmuno, 109-605-088) diluted 1:800 is added to each well, and the 96-well plate is incubated at 4° C. for 0.5 hours. The cells are washed twice with PBS solution containing 2% FBS, then resuspended in 120 μL of PBS, and the cell surface fluorescence signal is detected using a flow cytometer (BD FACS Celesta), obtaining the median fluorescence intensity (MFI). A dose-response curve is generated, and the half-maximal effective concentration (EC50) is calculated using non-linear regression with GraphPad software.

TABLE 3 Binding affinity to Hela cell of Humanized 26A12C1 antibody Humanized antibody NO. EC50(nM) hz26A12C1H1L1 N/A hz26A12C1H1L2 N/A hz26A12C1H1L3 N/A hz26A12C1H2L1 24.69 hz26A12C1H2L2 7.819 hz26A12C1H2L3 0.8529 hz26A12C1H3L1 2.988 hz26A12C1H3L2 2.333 hz26A12C1H3L3 0.838 hz26A12C1H4L1 0.646 hz26A12C1H4L2 0.5621 hz26A12C1H4L3 0.7378

TABLE 4 Binding affinity to Hela cell of Humanized 49E10H1 antibody Humanized antibody NO. EC50(nM) hz49E10H1H4L5 2.15 hz49E10H1H4L6 0.8533 hz49E10H1H4L7 0.6764 hz49E10H1H5L5 0.6326 hz49E10H1H5L6 0.4042 hz49E10H1H5L7 0.3767 hz49E10H1H6L5 24.33 hz49E10H1H6L6 1.03 hz49E10H1H6L7 0.9962 hz49E10H1H7L5 10.39 hz49E10H1H7L6 1.051 hz49E10H1H7L7 0.8516 hz49E10H1H8L5 9.274 hz49E10H1H8L6 1.06 hz49E10H1H8L7 0.8204

TABLE 5 Binding affinity to Hela cell of Humanized 103E9B3 antibody Humanized antibody NO. EC50(nM) ch103E9B3 1.21 hz103E9B3H5L4 6.845 hz103E9B3H5L5 1.682 hz103E9B3H5L6 1.926 hz103E9B3H6L4 6.595 hz103E9B3H6L5 1.483 hz103E9B3H6L6 2.184 hz103E9B3H7L4 5.323 hz103E9B3H7L5 2.133 hz103E9B3H7L6 2.034 hz103E9B3H8L4 5.795 hz103E9B3H8L5 1.54 hz103E9B3H8L6 1.997 hz103E9B3H9L4 5.564 hz103E9B3H9L5 1.964 hz103E9B3H9L6 2.065

In the present invention, the humanized antibody number is indicated as “hz+hybridoma clone number+heavy chain number+light chain number”, for example, the humanized antibody “hz46F1D5H1L2” represents a humanized antibody derived from the mouse anti-L1CAM monoclonal antibody 46F1D5, and the variable region heavy chain is VH1 (i.e., SEQ ID NO: 60), and the variable region light chain is VL2 (i.e., SEQ ID NO: 65).

In the present invention, the human-mouse chimeric antibody number is indicated as “ch+ hybridoma clone number”, for example, the human-mouse chimeric antibody “ch46F1D5” represents the human-mouse chimeric antibody derived from the mouse anti-L1CAM monoclonal antibody 46F1D5, and the variable region heavy chain is the heavy chain variable region of the mouse monoclonal antibody 46F1D5, the variable region light chain is the light chain variable region of the mouse monoclonal antibody 46F1D5, and the constant region is the human IgG1 constant region.

TABLE 6 Mouse monoclonal antibody complementary determinant amino acid sequence Antibody SEQ ID NO. Amino acid Sequence NO. 25F8H8 HCDR HCDR1 TYWMH 1 HCDR2 YINPSTGYTDYNQKFKD 2 HCDR3 RQLGLPLFDY 3 LCDR LCDR1 KASQDVGTAVA 4 LCDR2 WASTRHT 5 LCDR3 QQYSNYPLT 6 26A12C1 HCDR HCDR1 GYTFTNYW 7 HCDR2 INPSTYYS 8 HCDR3 ARRQFGLPLFDY 9 LCDR LCDR1 QDVGTA 10 LCDR2 WAS 11 LCDR3 QQYSNYPLT 12 46F1D5 HCDR HCDR1 GYTFTRYW 13 HCDR2 INPSTGYT 14 HCDR3 ARRHLGLPLFDY 15 LCDR LCDR1 QDVGTA 16 LCDR2 WAS 17 LCDR3 QQYSNYPLT 18 49E10H1 HCDR HCDR1 GYSITSDYA 19 HCDR2 ITYSGTT 20 HCDR3 TLDHYGNYAYFDY 21 LCDR LCDR1 SSVSF 22 LCDR2 ASS 23 LCDR3 QQWSSNPST 24 49′E10H1 HCDR HCDR1 GGSISSDYA 25 HCDR2 ITYSGTT 26 HCDR3 ARDHYGNYAYFDY 27 LCDR LCDR1 SSVSF 28 LCDR2 ASS 29 LCDR3 QQWSSNPST 30 49″E10H1 HCDR HCDR1 GGSISSDYA 31 HCDR2 ITYSGTT 32 HCDR3 TLDHYGNYAYFDY 33 LCDR LCDR1 SSVSF 34 LCDR2 ASS 35 LCDR3 QQWSSNPST 36 103E9B3 HCDR HCDR1 GYTFTSYT 37 HCDR2 INPNYGGT 38 HCDR3 AREGATGTWYFDV 39 LCDR LCDR1 SSVSF 40 LCDR2 LTS 41 LCDR3 QQWRSNPPT 42

TABLE 7 Mouse monoclonal antibody amino acid sequence SEQ ID Antibody Amino acid sequence NO. 25F8H8 Variable QVQLQQSGAELAKPGASVKMSCQASGYTF 43 full length TTYWMHWVKQRPGQGLEWIGYINPSTGYT of heavy DYNQKFKDKATLTADKSSSTAYMQLSSLTS chain EDSAVYYCARRQLGLPLFDYWGQGTTLTV (VH) SS Variable DIVMTQSHKFLSTSVGDRVSITCKASQDVG 44 full length TAVAWYQHKPGQSPKLLIFWASTRHTGVPD of light RFTGSGSGTDFTLTISNVQSEDLADYFCQQY chain (VL) SNYPLTFGAGPKLELK 26A12C1 Variable MERHWIFLFLFSATAGVHSQVQLQQSGAEL 45 full length AKPGASVKMSCKASGYTFTNYWMQWVKQ of heavy RPGQGLEWIGYINPSTYYSDYNQKFKDKAT chain LTADKSSSTAFMQLSSLTSEDSAVYYCARRQ (VH) FGLPLFDYWGQGTTLTLSS Variable METHSQVFVYMLLWLSGVEGDIVMTQSHK 46 full length FMSTSVGDRVSITCKASQDVGTAVAWYQQK of light PGQSPKLLIYWASTRHTGVPDRFTGSGSGT chain (VL) DFTLTISNVQSEDLTDYFCQQYSNYPLTFGA GTELELK 46F1D5 Variable MERHWIFLFLFSVTAGVYSQVQVQQSGAEL 47 full length AKPGASMKMSCKASGYTFTRYWMQWVK of heavy QRPGQGLEWIGYINPSTGYTDYNQNFKDK chain ATLTADKSSSTAYMQLSSLTSEDSAVYYCAR (VH) RHLGLPLFDYWGQGTTLTVSS Variable METHSQVFVYMLLWLSGVEGDIVMTQSHK 48 full length FMSTSLGDRVSITCKASQDVGTAVAWYQQK of light PGQSPKLLIYWASTRHTGVPDRFTGSGSGT chain (VL) DFTLTISNVQSEDLAEYFCQQYSNYPLTFGA GTKLDLK 49E10H1 Variable MRVLILLWLFTAFPGILSDVQLQESGPGLVK 49 full length PSQSLSLTCTVTGYSITSDYAWNWIRQFPGN of heavy RLEWMGYITYSGTTTYNPSLKSRISITRDTS chain KNQFFLQLNSVTTADTATYYCTLDHYGNYA (VH) YFDYWGQGTTLTVSS Variable MDFQVQIFSFLLISASVIMSRGQIVLSQSPAI 50 full length LSASPGEKVTMTCRASSSVSFMHWYQQKP of light RSSPKPWIYASSNLVSGVPTRFSGSGSGTSY chain (VL) SLTISRVEAEDAATYYCQQWSSNPSTFGAGT KLELK 103E9B3 Variable MGWSWIFLFLLSGTAGVLSEVQLQQSGPEL 51 full length LKPGASVKISCKASGYTFTSYTMHWVKQS of heavy HGKSLEWIGDINPNYGGTSYNEKFKDKATL chain TVDKSSSTAYMELRSLTSEDSAVYYCAREG (VH) ATGTWYFDVWGTGTTVTVSS Variable MDFQVQIFSFLLMSASVIMSRGQIVLTQSPA 52 full length LMSASPGEKVTMTCSASSSVSFMFWYQQK of light PRSSPKPWIYLTSNLASGVPARFSGSGSGTS chain (VL) YSLTISSMEAEDAATYYCQQWRSNPPTFGA GTKLELK

TABLE 8 Humanized monoclonal antibody variable region amino acid sequence SEQ Antibody ID NO. NO: Amino acid sequence hz26A12C1H1L1 VH 53 QVQLVQSGAEVKKPGSSVKVSCKASGYT FTNYWISWVRQAPGQGLEWMGGINPSTY YSNYAQKFQGRVTITADESTSTAYMELS SLRSEDTAVYYCARRQFGLPLFDYWGQG TTVTVSS VL 57 DIQMTQSPSSLSASVGDRVTITCRASQD VGTALAWYQQKPGKVPKLLIYWASTLQS GVPSRFSGSGSGTDFTLTISSLQPEDVA TYYCQQYSNYPLTFGGGTKVEIK hz26A12C1H1L2 VH 53 QVQLVQSGAEVKKPGSSVKVSCKASGYT FTNYWISWVRQAPGQGLEWMGGINPSTY YSNYAQKFQGRVTITADESTSTAYMELS SLRSEDTAVYYCARRQFGLPLFDYWGQG TTVTVSS VL 58 DIQMTQSPSSLSASVGDRVTITCRASQD VGTAVAWYQQKPGKVPKLLIYWASTLHS GVPSRFSGSGSGTDFTLTISSLQPEDVA TYYCQQYSNYPLTFGGGTKVEIK hz26A12C1H1L3 VH 53 QVQLVQSGAEVKKPGSSVKVSCKASGYT FTNYWISWVRQAPGQGLEWMGGINPSTY YSNYAQKFQGRVTITADESTSTAYMELS SLRSEDTAVYYCARRQFGLPLFDYWGQG TTVTVSS VL 59 DIQMTQSPSSLSASVGDRVTITCRASQD VGTAVAWYQQKPGKVPKLLIYWASTLHS GVPSRFSGSGSGTDFTLTISSLQPEDVA TYFCQQYSNYPLTFGGGTKVEIK hz26A12C1H2L1 VH 54 QVQLVQSGAEVKKPGSSVKVSCKASGYT FTNYWIQWVRQAPGQGLEWMGYINPSTY YSDYAQKFQGRVTITADESTSTAYMELS SLRSEDTAVYYCARRQFGLPLFDYWGQG TTVTVSS VL 57 DIQMTQSPSSLSASVGDRVTITCRASQD VGTALAWYQQKPGKVPKLLIYWASTLQS GVPSRFSGSGSGTDFTLTISSLQPEDVA TYYCQQYSNYPLTFGGGTKVEIK hz26A12C1H2L2 VH 54 QVQLVQSGAEVKKPGSSVKVSCKASGYT FTNYWIQWVRQAPGQGLEWMGYINPSTY YSDYAQKFQGRVTITADESTSTAYMELS SLRSEDTAVYYCARRQFGLPLFDYWGQG TTVTVSS VL 58 DIQMTQSPSSLSASVGDRVTITCRASQD VGTAVAWYQQKPGKVPKLLIYWASTLHS GVPSRFSGSGSGTDFTLTISSLQPEDVA TYYCQQYSNYPLTFGGGTKVEIK hz26A12C1H2L3 VH 54 QVQLVQSGAEVKKPGSSVKVSCKASGYT FTNYWIQWVRQAPGQGLEWMGYINPSTY YSDYAQKFQGRVTITADESTSTAYMELS SLRSEDTAVYYCARRQFGLPLFDYWGQG TTVTVSS VL 59 DIQMTQSPSSLSASVGDRVTITCRASQD VGTAVAWYQQKPGKVPKLLIYWASTLHS GVPSRFSGSGSGTDFTLTISSLQPEDVA TYFCQQYSNYPLTFGGGTKVEIK hz26A12C1H3L1 VH 55 QVQLVQSGAEVKKPGSSVKVSCKASGYT FTNYWIQWVRQAPGQGLEWIGYINPSTY YSDYAQKFQGRVTLTADESTSTAYMELS SLRSEDTAVYYCARRQFGLPLFDYWGQG TTVTVSS VL 57 DIQMTQSPSSLSASVGDRVTITCRASQD VGTALAWYQQKPGKVPKLLIYWASTLQS GVPSRFSGSGSGTDFTLTISSLQPEDVA TYYCQQYSNYPLTFGGGTKVEIK hz26A12C1H3L2 VH 55 QVQLVQSGAEVKKPGSSVKVSCKASGYT FTNYWIQWVRQAPGQGLEWIGYINPSTY YSDYAQKFQGRVTLTADESTSTAYMELS SLRSEDTAVYYCARRQFGLPLFDYWGQG TTVTVSS VL 58 DIQMTQSPSSLSASVGDRVTITCRASQD VGTAVAWYQQKPGKVPKLLIYWASTLHS GVPSRFSGSGSGTDFTLTISSLQPEDVA TYYCQQYSNYPLTFGGGTKVEIK hz26A12C1H3L3 VH 55 QVQLVQSGAEVKKPGSSVKVSCKASGYT FTNYWIQWVRQAPGQGLEWIGYINPSTY YSDYAQKFQGRVTLTADESTSTAYMELS SLRSEDTAVYYCARRQFGLPLFDYWGQG TTVTVSS VL 59 DIQMTQSPSSLSASVGDRVTITCRASQD VGTAVAWYQQKPGKVPKLLIYWASTLHS GVPSRFSGSGSGTDFTLTISSLQPEDVA TYFCQQYSNYPLTFGGGTKVEIK hz26A12C1H4L1 VH 56 QVQLVQSGAEVKKPGSSVKVSCKASGYT FTNYWIQWVRQAPGQGLEWIGYINPSTY YSDYNQKFQGRVTLTADKSTSTAYMELS SLRSEDTAVYYCARRQFGLPLFDYWGQG TTVTVSS VL 57 DIQMTQSPSSLSASVGDRVTITCRASQD VGTALAWYQQKPGKVPKLLIYWASTLQS GVPSRFSGSGSGTDFTLTISSLQPEDVA TYYCQQYSNYPLTFGGGTKVEIK hz26A12C1H4L2 VH 56 QVQLVQSGAEVKKPGSSVKVSCKASGYT FTNYWIQWVRQAPGQGLEWIGYINPSTY YSDYNQKFQGRVTLTADKSTSTAYMELS SLRSEDTAVYYCARRQFGLPLFDYWGQG TTVTVSS VL 58 DIQMTQSPSSLSASVGDRVTITCRASQD VGTAVAWYQQKPGKVPKLLIYWASTLHS GVPSRFSGSGSGTDFTLTISSLQPEDVA TYYCQQYSNYPLTFGGGTKVEIK hz26A12C1H4L3 VH 56 QVQLVQSGAEVKKPGSSVKVSCKASGYT FTNYWIQWVRQAPGQGLEWIGYINPSTY YSDYNQKFQGRVTLTADKSTSTAYMELS SLRSEDTAVYYCARRQFGLPLFDYWGQG TTVTVSS VL 59 DIQMTQSPSSLSASVGDRVTITCRASQD VGTAVAWYQQKPGKVPKLLIYWASTLHS GVPSRFSGSGSGTDFTLTISSLQPEDVA TYFCQQYSNYPLTFGGGTKVEIK hz46F1D5H1L1 VH 60 QVQLVQSGAEVKKPGSSVKVSCKASGYT FTRYWISWVRQAPGQGLEWMGGINPSTG YTNYAQKFQGRVTITADESTSTAYMELS SLRSEDTAVYYCARRHLGLPLFDYWGQG TTVTVSS VL 64 DIQMTQSPSSVSASVGDRVTITCRASQD VGTALAWYQQKPGKAPKLLIYWASSLQS GVPSRFSGSGSGTDFTLTISSLQPEDFA TYYCQQYSNYPLTFGGGTKVEIK hz46F1D5H1L2 VH 60 QVQLVQSGAEVKKPGSSVKVSCKASGYT FTRYWISWVRQAPGQGLEWMGGINPSTG YTNYAQKFQGRVTITADESTSTAYMELS SLRSEDTAVYYCARRHLGLPLFDYWGQG TTVTVSS VL 65 DIQMTQSPSSVSASVGDRVTITCRASQD VGTALAWYQQKPGKAPKLLIYWASSLHS GVPSRFSGSGSGTDFTLTISSLQPEDFA TYYCQQYSNYPLTFGGGTKVEIK hz46F1D5H1L3 VH 60 QVQLVQSGAEVKKPGSSVKVSCKASGYT FTRYWISWVRQAPGQGLEWMGGINPSTG YTNYAQKFQGRVTITADESTSTAYMELS SLRSEDTAVYYCARRHLGLPLFDYWGQG TTVTVSS VL 66 DIQMTQSPSSVSASVGDRVTITCRASQD VGTAVAWYQQKPGKAPKLLIYWASSLHS GVPSRFSGSGSGTDFTLTISSLQPEDFA TYFCQQYSNYPLTFGGGTKVEIK hz46F1D5H2L1 VH 61 QVQLVQSGAEVKKPGSSVKVSCKASGYT FTRYWIQWVRQAPGQGLEWMGYINPSTG YTNYAQKFQGRVTITADESTSTAYMELS SLRSEDTAVYYCARRHLGLPLFDYWGQG TTVTVSS VL 64 DIQMTQSPSSVSASVGDRVTITCRASQD VGTALAWYQQKPGKAPKLLIYWASSLQS GVPSRFSGSGSGTDFTLTISSLQPEDFA TYYCQQYSNYPLTFGGGTKVEIK hz46F1D5H2L2 VH 61 QVQLVQSGAEVKKPGSSVKVSCKASGYT FTRYWIQWVRQAPGQGLEWMGYINPSTG YTNYAQKFQGRVTITADESTSTAYMELS SLRSEDTAVYYCARRHLGLPLFDYWGQG TTVTVSS VL 65 DIQMTQSPSSVSASVGDRVTITCRASQD VGTALAWYQQKPGKAPKLLIYWASSLHS GVPSRFSGSGSGTDFTLTISSLQPEDFA TYYCQQYSNYPLTFGGGTKVEIK hz46F1D5H2L3 VH 61 QVQLVQSGAEVKKPGSSVKVSCKASGYT FTRYWIQWVRQAPGQGLEWMGYINPSTG YTNYAQKFQGRVTITADESTSTAYMELS SLRSEDTAVYYCARRHLGLPLFDYWGQG TTVTVSS VL 66 DIQMTQSPSSVSASVGDRVTITCRASQD VGTAVAWYQQKPGKAPKLLIYWASSLHS GVPSRFSGSGSGTDFTLTISSLQPEDFA TYFCQQYSNYPLTFGGGTKVEIK hz46F1D5H3L1 VH 62 QVQLVQSGAEVKKPGSSVKVSCKASGYT FTRYWIQWVRQAPGQGLEWMGYINPSTG YTDYNQKFQGRVTITADESTSTAYMELS SLRSEDTAVYYCARRHLGLPLFDYWGQG TTVTVSS VL 64 DIQMTQSPSSVSASVGDRVTITCRASQD VGTALAWYQQKPGKAPKLLIYWASSLQS GVPSRFSGSGSGTDFTLTISSLQPEDFA TYYCQQYSNYPLTFGGGTKVEIK hz46F1D5H3L2 VH 62 QVQLVQSGAEVKKPGSSVKVSCKASGYT FTRYWIQWVRQAPGQGLEWMGYINPSTG YTDYNQKFQGRVTITADESTSTAYMELS SLRSEDTAVYYCARRHLGLPLFDYWGQG TTVTVSS VL 65 DIQMTQSPSSVSASVGDRVTITCRASQD VGTALAWYQQKPGKAPKLLIYWASSLHS GVPSRFSGSGSGTDFTLTISSLQPEDFA TYYCQQYSNYPLTFGGGTKVEIK hz46F1D5H3L3 VH 62 QVQLVQSGAEVKKPGSSVKVSCKASGYT FTRYWIQWVRQAPGQGLEWMGYINPSTG YTDYNQKFQGRVTITADESTSTAYMELS SLRSEDTAVYYCARRHLGLPLFDYWGQG TTVTVSS VL 66 DIQMTQSPSSVSASVGDRVTITCRASQD VGTAVAWYQQKPGKAPKLLIYWASSLHS GVPSRFSGSGSGTDFTLTISSLQPEDFA TYFCQQYSNYPLTFGGGTKVEIK hz46F1D5H4L1 VH 63 QVQLVQSGAEVKKPGSSVKVSCKASGYT FTRYWIQWVRQAPGQGLEWMGYINPSTG YTDYNQKFQGRVTITADKSTSTAYMELS SLRSEDTAVYYCARRHLGLPLFDYWGQG TTVTVSS VL 64 DIQMTQSPSSVSASVGDRVTITCRASQD VGTALAWYQQKPGKAPKLLIYWASSLQS GVPSRFSGSGSGTDFTLTISSLQPEDFA TYYCQQYSNYPLTFGGGTKVEIK hz46F1D5H4L2 VH 63 QVQLVQSGAEVKKPGSSVKVSCKASGYT FTRYWIQWVRQAPGQGLEWMGYINPSTG YTDYNQKFQGRVTITADKSTSTAYMELS SLRSEDTAVYYCARRHLGLPLFDYWGQG TTVTVSS VL 65 DIQMTQSPSSVSASVGDRVTITCRASQD VGTALAWYQQKPGKAPKLLIYWASSLHS GVPSRFSGSGSGTDFTLTISSLQPEDFA TYYCQQYSNYPLTFGGGTKVEIK hz46F1D5H4L3 VH 63 QVQLVQSGAEVKKPGSSVKVSCKASGYT FTRYWIQWVRQAPGQGLEWMGYINPSTG YTDYNQKFQGRVTITADKSTSTAYMELS SLRSEDTAVYYCARRHLGLPLFDYWGQG TTVTVSS VL 66 DIQMTQSPSSVSASVGDRVTITCRASQD VGTAVAWYQQKPGKAPKLLIYWASSLHS GVPSRFSGSGSGTDFTLTISSLQPEDFA TYFCQQYSNYPLTFGGGTKVEIK hz49E10H1H1L1 VH 67 QVQLQESGPGLVKPSQTLSLTCTVSGYS ITSDYAWSWIRQPPGKGLEWIGYITYSG TTYYNPSLKSRVTISVDTSKNQFSLKLS SVTAADTAVYYCTLDHYGNYAYFDYWGQ GTTVTVSS VL 75 DIQMTQSPSSLSASVGDRVTITCRASSS VSFLNWYQQKPGKAPKLLIYASSSLQSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H1L2 VH 67 QVQLQESGPGLVKPSQTLSLTCTVSGYS ITSDYAWSWIRQPPGKGLEWIGYITYSG TTYYNPSLKSRVTISVDTSKNQFSLKLS SVTAADTAVYYCTLDHYGNYAYFDYWGQ GTTVTVSS VL 76 DIQMTQSPSSLSASVGDRVTITCRASSS VSFLHWYQQKPGKAPKLLIYASSSLQSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H1L3 VH 67 QVQLQESGPGLVKPSQTLSLTCTVSGYS ITSDYAWSWIRQPPGKGLEWIGYITYSG TTYYNPSLKSRVTISVDTSKNQFSLKLS SVTAADTAVYYCTLDHYGNYAYFDYWGQ GTTVTVSS VL 77 DIQMTQSPSSLSASVGDRVTITCRASSS VSFMHWYQQKPGKAPKLLIYASSSLQSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H1L4 VH 67 QVQLQESGPGLVKPSQTLSLTCTVSGYS ITSDYAWSWIRQPPGKGLEWIGYITYSG TTYYNPSLKSRVTISVDTSKNQFSLKLS SVTAADTAVYYCTLDHYGNYAYFDYWGQ GTTVTVSS VL 78 DIQMTQSPSSLSASVGDRVTITCRASSS VSFMHWYQQKPGKAPKPLIYASSSLQSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H1L5 VH 67 QVQLQESGPGLVKPSQTLSLTCTVSGYS ITSDYAWSWIRQPPGKGLEWIGYITYSG TTYYNPSLKSRVTISVDTSKNQFSLKLS SVTAADTAVYYCTLDHYGNYAYFDYWGQ GTTVTVSS VL 79 DIQMTQSPSSLSASVGDRVTITCRASSS VSFMHWYQQKPGKAPKLLIYASSNLVSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H1L6 VH 67 QVQLQESGPGLVKPSQTLSLTCTVSGYS ITSDYAWSWIRQPPGKGLEWIGYITYSG TTYYNPSLKSRVTISVDTSKNQFSLKLS SVTAADTAVYYCTLDHYGNYAYFDYWGQ GTTVTVSS VL 80 DIQMTQSPSSLSASVGDRVTITCRASSS VSFMHWYQQKPGKAPKPWIYASSNLVSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H1L7 VH 67 QVQLQESGPGLVKPSQTLSLTCTVSGYS ITSDYAWSWIRQPPGKGLEWIGYITYSG TTYYNPSLKSRVTISVDTSKNQFSLKLS SVTAADTAVYYCTLDHYGNYAYFDYWGQ GTTVTVSS VL 81 QIQMTQSPSSLSASVGDRVTITCRASSS VSFMHWYQQKPGKAPKPWIYASSNLVSG VPSRFSGSGSGTDYTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H2L1 VH 68 DVQLQESGPGLVKPSQTLSLTCTVSGYS ITSDYAWNWIRQPPGKGLEWIGYITYSG TTYYNPSLKSRVTISVDTSKNQFSLKLS SVTAADTAVYYCTLDHYGNYAYFDYWGQ GTTVTVSS VL 75 DIQMTQSPSSLSASVGDRVTITCRASSS VSFLNWYQQKPGKAPKLLIYASSSLQSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H2L2 VH 68 DVQLQESGPGLVKPSQTLSLTCTVSGYS ITSDYAWNWIRQPPGKGLEWIGYITYSG TTYYNPSLKSRVTISVDTSKNQFSLKLS SVTAADTAVYYCTLDHYGNYAYFDYWGQ GTTVTVSS VL 76 DIQMTQSPSSLSASVGDRVTITCRASSS VSFLHWYQQKPGKAPKLLIYASSSLQSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H2L3 VH 68 DVQLQESGPGLVKPSQTLSLTCTVSGYS ITSDYAWNWIRQPPGKGLEWIGYITYSG TTYYNPSLKSRVTISVDTSKNQFSLKLS SVTAADTAVYYCTLDHYGNYAYFDYWGQ GTTVTVSS VL 77 DIQMTQSPSSLSASVGDRVTITCRASSS VSFMHWYQQKPGKAPKLLIYASSSLQSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H2L4 VH 68 DVQLQESGPGLVKPSQTLSLTCTVSGYS ITSDYAWNWIRQPPGKGLEWIGYITYSG TTYYNPSLKSRVTISVDTSKNQFSLKLS SVTAADTAVYYCTLDHYGNYAYFDYWGQ GTTVTVSS VL 78 DIQMTQSPSSLSASVGDRVTITCRASSS VSFMHWYQQKPGKAPKPLIYASSSLQSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H2L5 VH 68 DVQLQESGPGLVKPSQTLSLTCTVSGYS ITSDYAWNWIRQPPGKGLEWIGYITYSG TTYYNPSLKSRVTISVDTSKNQFSLKLS SVTAADTAVYYCTLDHYGNYAYFDYWGQ GTTVTVSS VL 79 DIQMTQSPSSLSASVGDRVTITCRASSS VSFMHWYQQKPGKAPKLLIYASSNLVSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H2L6 VH 68 DVQLQESGPGLVKPSQTLSLTCTVSGYS ITSDYAWNWIRQPPGKGLEWIGYITYSG TTYYNPSLKSRVTISVDTSKNQFSLKLS SVTAADTAVYYCTLDHYGNYAYFDYWGQ GTTVTVSS VL 80 DIQMTQSPSSLSASVGDRVTITCRASSS VSFMHWYQQKPGKAPKPWIYASSNLVSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H2L7 VH 68 DVQLQESGPGLVKPSQTLSLTCTVSGYS ITSDYAWNWIRQPPGKGLEWIGYITYSG TTYYNPSLKSRVTISVDTSKNQFSLKLS SVTAADTAVYYCTLDHYGNYAYFDYWGQ GTTVTVSS VL 81 QIQMTQSPSSLSASVGDRVTITCRASSS VSFMHWYQQKPGKAPKPWIYASSNLVSG VPSRFSGSGSGTDYTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H3L1 VH 69 DVQLQESGPGLVKPSQTLSLTCTVSGYS ITSDYAWNWIRQPPGKGLEWMGYITYSG TTYYNPSLKSRVTISRDTSKNQFSLKLS SVTAADTAVYYCTLDHYGNYAYFDYWGQ GTTVTVSS VL 75 DIQMTQSPSSLSASVGDRVTITCRASSS VSFLNWYQQKPGKAPKLLIYASSSLQSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H3L2 VH 69 DVQLQESGPGLVKPSQTLSLTCTVSGYS ITSDYAWNWIRQPPGKGLEWMGYITYSG TTYYNPSLKSRVTISRDTSKNQFSLKLS SVTAADTAVYYCTLDHYGNYAYFDYWGQ GTTVTVSS VL 76 DIQMTQSPSSLSASVGDRVTITCRASSS VSFLHWYQQKPGKAPKLLIYASSSLQSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H3L3 VH 69 DVQLQESGPGLVKPSQTLSLTCTVSGYS ITSDYAWNWIRQPPGKGLEWMGYITYSG TTYYNPSLKSRVTISRDTSKNQFSLKLS SVTAADTAVYYCTLDHYGNYAYFDYWGQ GTTVTVSS VL 77 DIQMTQSPSSLSASVGDRVTITCRASSS VSFMHWYQQKPGKAPKLLIYASSSLQSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H3L4 VH 69 DVQLQESGPGLVKPSQTLSLTCTVSGYS ITSDYAWNWIRQPPGKGLEWMGYITYSG TTYYNPSLKSRVTISRDTSKNQFSLKLS SVTAADTAVYYCTLDHYGNYAYFDYWGQ GTTVTVSS VL 78 DIQMTQSPSSLSASVGDRVTITCRASSS VSFMHWYQQKPGKAPKPLIYASSSLQSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H3L5 VH 69 DVQLQESGPGLVKPSQTLSLTCTVSGYS ITSDYAWNWIRQPPGKGLEWMGYITYSG TTYYNPSLKSRVTISRDTSKNQFSLKLS SVTAADTAVYYCTLDHYGNYAYFDYWGQ GTTVTVSS VL 79 DIQMTQSPSSLSASVGDRVTITCRASSS VSFMHWYQQKPGKAPKLLIYASSNLVSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H3L6 VH 69 DVQLQESGPGLVKPSQTLSLTCTVSGYS ITSDYAWNWIRQPPGKGLEWMGYITYSG TTYYNPSLKSRVTISRDTSKNQFSLKLS SVTAADTAVYYCTLDHYGNYAYFDYWGQ GTTVTVSS VL 80 DIQMTQSPSSLSASVGDRVTITCRASSS VSFMHWYQQKPGKAPKPWIYASSNLVSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H3L7 VH 69 DVQLQESGPGLVKPSQTLSLTCTVSGYS ITSDYAWNWIRQPPGKGLEWMGYITYSG TTYYNPSLKSRVTISRDTSKNQFSLKLS SVTAADTAVYYCTLDHYGNYAYFDYWGQ GTTVTVSS VL 81 QIQMTQSPSSLSASVGDRVTITCRASSS VSFMHWYQQKPGKAPKPWIYASSNLVSG VPSRFSGSGSGTDYTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H4L1 VH 70 QVQLQESGPGLVKPSQTLSLTCTVSGGS ISSDYAWNWIRQPPGKGLEWIGYITYSG TTTYNPSLKSRVTISVDTSKNQFSLKLS SVTAADTAVYYCARDHYGNYAYFDYWGQ GTTVTVSS VL 75 DIQMTQSPSSLSASVGDRVTITCRASSS VSFLNWYQQKPGKAPKLLIYASSSLQSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H4L2 VH 70 QVQLQESGPGLVKPSQTLSLTCTVSGGS ISSDYAWNWIRQPPGKGLEWIGYITYSG TTTYNPSLKSRVTISVDTSKNQFSLKLS SVTAADTAVYYCARDHYGNYAYFDYWGQ GTTVTVSS VL 76 DIQMTQSPSSLSASVGDRVTITCRASSS VSFLHWYQQKPGKAPKLLIYASSSLQSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H4L3 VH 70 QVQLQESGPGLVKPSQTLSLTCTVSGGS ISSDYAWNWIRQPPGKGLEWIGYITYSG TTTYNPSLKSRVTISVDTSKNQFSLKLS SVTAADTAVYYCARDHYGNYAYFDYWGQ GTTVTVSS VL 77 DIQMTQSPSSLSASVGDRVTITCRASSS VSFMHWYQQKPGKAPKLLIYASSSLQSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H4L4 VH 70 QVQLQESGPGLVKPSQTLSLTCTVSGGS ISSDYAWNWIRQPPGKGLEWIGYITYSG TTTYNPSLKSRVTISVDTSKNQFSLKLS SVTAADTAVYYCARDHYGNYAYFDYWGQ GTTVTVSS VL 78 DIQMTQSPSSLSASVGDRVTITCRASSS VSFMHWYQQKPGKAPKPLIYASSSLQSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H4L5 VH 70 QVQLQESGPGLVKPSQTLSLTCTVSGGS ISSDYAWNWIRQPPGKGLEWIGYITYSG TTTYNPSLKSRVTISVDTSKNQFSLKLS SVTAADTAVYYCARDHYGNYAYFDYWGQ GTTVTVSS VL 79 DIQMTQSPSSLSASVGDRVTITCRASSS VSFMHWYQQKPGKAPKLLIYASSNLVSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H4L6 VH 70 QVQLQESGPGLVKPSQTLSLTCTVSGGS ISSDYAWNWIRQPPGKGLEWIGYITYSG TTTYNPSLKSRVTISVDTSKNQFSLKLS SVTAADTAVYYCARDHYGNYAYFDYWGQ GTTVTVSS VL 80 DIQMTQSPSSLSASVGDRVTITCRASSS VSFMHWYQQKPGKAPKPWIYASSNLVSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H4L7 VH 70 QVQLQESGPGLVKPSQTLSLTCTVSGGS ISSDYAWNWIRQPPGKGLEWIGYITYSG TTTYNPSLKSRVTISVDTSKNQFSLKLS SVTAADTAVYYCARDHYGNYAYFDYWGQ GTTVTVSS VL 81 QIQMTQSPSSLSASVGDRVTITCRASSS VSFMHWYQQKPGKAPKPWIYASSNLVSG VPSRFSGSGSGTDYTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H5L1 VH 71 DVQLQESGPGLVKPSQTLSLTCTVSGGS ISSDYAWNWIRQPPGKGLEWMGYITYSG TTTYNPSLKSRITISRDTSKNQFSLKLS SVTAADTAVYYCARDHYGNYAYFDYWGQ GTTVTVSS VL 75 DIQMTQSPSSLSASVGDRVTITCRASSS VSFLNWYQQKPGKAPKLLIYASSSLQSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H5L2 VH 71 DVQLQESGPGLVKPSQTLSLTCTVSGGS ISSDYAWNWIRQPPGKGLEWMGYITYSG TTTYNPSLKSRITISRDTSKNQFSLKLS SVTAADTAVYYCARDHYGNYAYFDYWGQ GTTVTVSS VL 76 DIQMTQSPSSLSASVGDRVTITCRASSS VSFLHWYQQKPGKAPKLLIYASSSLQSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H5L3 VH 71 DVQLQESGPGLVKPSQTLSLTCTVSGGS ISSDYAWNWIRQPPGKGLEWMGYITYSG TTTYNPSLKSRITISRDTSKNQFSLKLS SVTAADTAVYYCARDHYGNYAYFDYWGQ GTTVTVSS VL 77 DIQMTQSPSSLSASVGDRVTITCRASSS VSFMHWYQQKPGKAPKLLIYASSSLQSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H5L4 VH 71 DVQLQESGPGLVKPSQTLSLTCTVSGGS ISSDYAWNWIRQPPGKGLEWMGYITYSG TTTYNPSLKSRITISRDTSKNQFSLKLS SVTAADTAVYYCARDHYGNYAYFDYWGQ GTTVTVSS VL 78 DIQMTQSPSSLSASVGDRVTITCRASSS VSFMHWYQQKPGKAPKPLIYASSSLQSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H5L5 VH 71 DVQLQESGPGLVKPSQTLSLTCTVSGGS ISSDYAWNWIRQPPGKGLEWMGYITYSG TTTYNPSLKSRITISRDTSKNQFSLKLS SVTAADTAVYYCARDHYGNYAYFDYWGQ GTTVTVSS VL 79 DIQMTQSPSSLSASVGDRVTITCRASSS VSFMHWYQQKPGKAPKLLIYASSNLVSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H5L6 VH 71 DVQLQESGPGLVKPSQTLSLTCTVSGGS ISSDYAWNWIRQPPGKGLEWMGYITYSG TTTYNPSLKSRITISRDTSKNQFSLKLS SVTAADTAVYYCARDHYGNYAYFDYWGQ GTTVTVSS VL 80 DIQMTQSPSSLSASVGDRVTITCRASSS VSFMHWYQQKPGKAPKPWIYASSNLVSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H5L7 VH 71 DVQLQESGPGLVKPSQTLSLTCTVSGGS ISSDYAWNWIRQPPGKGLEWMGYITYSG TTTYNPSLKSRITISRDTSKNQFSLKLS SVTAADTAVYYCARDHYGNYAYFDYWGQ GTTVTVSS VL 81 QIQMTQSPSSLSASVGDRVTITCRASSS VSFMHWYQQKPGKAPKPWIYASSNLVSG VPSRFSGSGSGTDYTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H6L1 VH 72 DVQLQESGPGLVKPSQTLSLTCTVSGGS ISSDYAWNWIRQPPGKGLEWIGYITYSG TTTYNPSLKSRVTISRDTSKNQFSLKLS SVTAADTAVYYCTLDHYGNYAYFDYWGQ GTTVTVSS VL 75 DIQMTQSPSSLSASVGDRVTITCRASSS VSFLNWYQQKPGKAPKLLIYASSSLQSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H6L2 VH 72 DVQLQESGPGLVKPSQTLSLTCTVSGGS ISSDYAWNWIRQPPGKGLEWIGYITYSG TTTYNPSLKSRVTISRDTSKNQFSLKLS SVTAADTAVYYCTLDHYGNYAYFDYWGQ GTTVTVSS VL 76 DIQMTQSPSSLSASVGDRVTITCRASSS VSFLHWYQQKPGKAPKLLIYASSSLQSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H6L3 VH 72 DVQLQESGPGLVKPSQTLSLTCTVSGGS ISSDYAWNWIRQPPGKGLEWIGYITYSG TTTYNPSLKSRVTISRDTSKNQFSLKLS SVTAADTAVYYCTLDHYGNYAYFDYWGQ GTTVTVSS VL 77 DIQMTQSPSSLSASVGDRVTITCRASSS VSFMHWYQQKPGKAPKLLIYASSSLQSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H6L4 VH 72 DVQLQESGPGLVKPSQTLSLTCTVSGGS ISSDYAWNWIRQPPGKGLEWIGYITYSG TTTYNPSLKSRVTISRDTSKNQFSLKLS SVTAADTAVYYCTLDHYGNYAYFDYWGQ GTTVTVSS VL 78 DIQMTQSPSSLSASVGDRVTITCRASSS VSFMHWYQQKPGKAPKPLIYASSSLQSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H6L5 VH 72 DVQLQESGPGLVKPSQTLSLTCTVSGGS ISSDYAWNWIRQPPGKGLEWIGYITYSG TTTYNPSLKSRVTISRDTSKNQFSLKLS SVTAADTAVYYCTLDHYGNYAYFDYWGQ GTTVTVSS VL 79 DIQMTQSPSSLSASVGDRVTITCRASSS VSFMHWYQQKPGKAPKLLIYASSNLVSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H6L6 VH 72 DVQLQESGPGLVKPSQTLSLTCTVSGGS ISSDYAWNWIRQPPGKGLEWIGYITYSG TTTYNPSLKSRVTISRDTSKNQFSLKLS SVTAADTAVYYCTLDHYGNYAYFDYWGQ GTTVTVSS VL 80 DIQMTQSPSSLSASVGDRVTITCRASSS VSFMHWYQQKPGKAPKPWIYASSNLVSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H6L7 VH 72 DVQLQESGPGLVKPSQTLSLTCTVSGGS ISSDYAWNWIRQPPGKGLEWIGYITYSG TTTYNPSLKSRVTISRDTSKNQFSLKLS SVTAADTAVYYCTLDHYGNYAYFDYWGQ GTTVTVSS VL 81 QIQMTQSPSSLSASVGDRVTITCRASSS VSFMHWYQQKPGKAPKPWIYASSNLVSG VPSRFSGSGSGTDYTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H7L1 VH 73 QVQLQESGPGLVKPSQTLSLTCTVSGGS ISSDYAWNWIRQPPGKGLEWMGYITYSG TTTYNPSLKSRITISRDTSKNQFSLKLS SVTAADTAVYYCTLDHYGNYAYFDYWGQ GTTVTVSS VL 75 DIQMTQSPSSLSASVGDRVTITCRASSS VSFLNWYQQKPGKAPKLLIYASSSLQSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H7L2 VH 73 QVQLQESGPGLVKPSQTLSLTCTVSGGS ISSDYAWNWIRQPPGKGLEWMGYITYSG TTTYNPSLKSRITISRDTSKNQFSLKLS SVTAADTAVYYCTLDHYGNYAYFDYWGQ GTTVTVSS VL 76 DIQMTQSPSSLSASVGDRVTITCRASSS VSFLHWYQQKPGKAPKLLIYASSSLQSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H7L3 VH 73 QVQLQESGPGLVKPSQTLSLTCTVSGGS ISSDYAWNWIRQPPGKGLEWMGYITYSG TTTYNPSLKSRITISRDTSKNQFSLKLS SVTAADTAVYYCTLDHYGNYAYFDYWGQ GTTVTVSS VL 77 DIQMTQSPSSLSASVGDRVTITCRASSS VSFMHWYQQKPGKAPKLLIYASSSLQSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H7L4 VH 73 QVQLQESGPGLVKPSQTLSLTCTVSGGS ISSDYAWNWIRQPPGKGLEWMGYITYSG TTTYNPSLKSRITISRDTSKNQFSLKLS SVTAADTAVYYCTLDHYGNYAYFDYWGQ GTTVTVSS VL 78 DIQMTQSPSSLSASVGDRVTITCRASSS VSFMHWYQQKPGKAPKPLIYASSSLQSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H7L5 VH 73 QVQLQESGPGLVKPSQTLSLTCTVSGGS ISSDYAWNWIRQPPGKGLEWMGYITYSG TTTYNPSLKSRITISRDTSKNQFSLKLS SVTAADTAVYYCTLDHYGNYAYFDYWGQ GTTVTVSS VL 79 DIQMTQSPSSLSASVGDRVTITCRASSS VSFMHWYQQKPGKAPKLLIYASSNLVSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H7L6 VH 73 QVQLQESGPGLVKPSQTLSLTCTVSGGS ISSDYAWNWIRQPPGKGLEWMGYITYSG TTTYNPSLKSRITISRDTSKNQFSLKLS SVTAADTAVYYCTLDHYGNYAYFDYWGQ GTTVTVSS VL 80 DIQMTQSPSSLSASVGDRVTITCRASSS VSFMHWYQQKPGKAPKPWIYASSNLVSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H7L7 VH 73 QVQLQESGPGLVKPSQTLSLTCTVSGGS ISSDYAWNWIRQPPGKGLEWMGYITYSG TTTYNPSLKSRITISRDTSKNQFSLKLS SVTAADTAVYYCTLDHYGNYAYFDYWGQ GTTVTVSS VL 81 QIQMTQSPSSLSASVGDRVTITCRASSS VSFMHWYQQKPGKAPKPWIYASSNLVSG VPSRFSGSGSGTDYTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H8L1 VH 74 DVQLQESGPGLVKPSQTLSLTCTVSGGS ISSDYAWNWIRQPPGNGLEWMGYITYSG TTTYNPSLKSRITISRDTSKNQFSLKLS SVTAADTAVYYCTLDHYGNYAYFDYWGQ GTTVTVSS VL 75 DIQMTQSPSSLSASVGDRVTITCRASSS VSFLNWYQQKPGKAPKLLIYASSSLQSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H8L2 VH 74 DVQLQESGPGLVKPSQTLSLTCTVSGGS ISSDYAWNWIRQPPGNGLEWMGYITYSG TTTYNPSLKSRITISRDTSKNQFSLKLS SVTAADTAVYYCTLDHYGNYAYFDYWGQ GTTVTVSS VL 76 DIQMTQSPSSLSASVGDRVTITCRASSS VSFLHWYQQKPGKAPKLLIYASSSLQSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H8L3 VH 74 DVQLQESGPGLVKPSQTLSLTCTVSGGS ISSDYAWNWIRQPPGNGLEWMGYITYSG TTTYNPSLKSRITISRDTSKNQFSLKLS SVTAADTAVYYCTLDHYGNYAYFDYWGQ GTTVTVSS VL 77 DIQMTQSPSSLSASVGDRVTITCRASSS VSFMHWYQQKPGKAPKLLIYASSSLQSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H8L4 VH 74 DVQLQESGPGLVKPSQTLSLTCTVSGGS ISSDYAWNWIRQPPGNGLEWMGYITYSG TTTYNPSLKSRITISRDTSKNQFSLKLS SVTAADTAVYYCTLDHYGNYAYFDYWGQ GTTVTVSS VL 78 DIQMTQSPSSLSASVGDRVTITCRASSS VSFMHWYQQKPGKAPKPLIYASSSLQSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H8L5 VH 74 DVQLQESGPGLVKPSQTLSLTCTVSGGS ISSDYAWNWIRQPPGNGLEWMGYITYSG TTTYNPSLKSRITISRDTSKNQFSLKLS SVTAADTAVYYCTLDHYGNYAYFDYWGQ GTTVTVSS VL 79 DIQMTQSPSSLSASVGDRVTITCRASSS VSFMHWYQQKPGKAPKLLIYASSNLVSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H8L6 VH 74 DVQLQESGPGLVKPSQTLSLTCTVSGGS ISSDYAWNWIRQPPGNGLEWMGYITYSG TTTYNPSLKSRITISRDTSKNQFSLKLS SVTAADTAVYYCTLDHYGNYAYFDYWGQ GTTVTVSS VL 80 DIQMTQSPSSLSASVGDRVTITCRASSS VSFMHWYQQKPGKAPKPWIYASSNLVSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz49E10H1H8L7 VH 74 DVQLQESGPGLVKPSQTLSLTCTVSGGS ISSDYAWNWIRQPPGNGLEWMGYITYSG TTTYNPSLKSRITISRDTSKNQFSLKLS SVTAADTAVYYCTLDHYGNYAYFDYWGQ GTTVTVSS VL 81 QIQMTQSPSSLSASVGDRVTITCRASSS VSFMHWYQQKPGKAPKPWIYASSNLVSG VPSRFSGSGSGTDYTLTISSLQPEDFAT YYCQQWSSNPSTFGGGTKVEIK hz103E9B3H1L1 VH 82 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWMGIINPNYG GTSYAQKFQGRVTMTRDTSTSTVYMELS SLRSEDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 91 DIQMTQSPSSLSASVGDRVTITCRASSS VSFLNWYQQKPGKAPKLLIYLTSSLQSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWRSNPPTFGGGTKVEIK hz103E9B3H1L2 VH 82 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWMGIINPNYG GTSYAQKFQGRVTMTRDTSTSTVYMELS SLRSEDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 92 DIQMTQSPSSLSASVGDRVTITCRASSS VSFLFWYQQKPGKAPKLLIYLTSSLASG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWRSNPPTFGGGTKVEIK hz103E9B3H1L3 VH 82 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWMGIINPNYG GTSYAQKFQGRVTMTRDTSTSTVYMELS SLRSEDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 93 DIQMTQSPSSLSASVGDRVTITCRASSS VSFMFWYQQKPGKAPKPLIYLTSSLASG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWRSNPPTFGGGTKVEIK hz103E9B3H1L4 VH 82 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWMGIINPNYG GTSYAQKFQGRVTMTRDTSTSTVYMELS SLRSEDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 94 DIQMTQSPSSLSASVGDRVTITCSASSS VSFMFWYQQKPGKAPKLLIYLTSNLASG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWRSNPPTFGGGTKVEIK hz103E9B3H1L5 VH 82 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWMGIINPNYG GTSYAQKFQGRVTMTRDTSTSTVYMELS SLRSEDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 95 DIQMTQSPSSLSASVGDRVTITCSASSS VSFMFWYQQKPGKAPKPLIYLTSNLASG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWRSNPPTFGGGTKVEIK hz103E9B3H1L6 VH 82 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWMGIINPNYG GTSYAQKFQGRVTMTRDTSTSTVYMELS SLRSEDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 96 DIQMTQSPSSLSASVGDRVTITCSASSS VSFMFWYQQKPGKAPKPWIYLTSNLASG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWRSNPPTFGGGTKVEIK hz103E9B3H2L1 VH 83 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWMGDINPNYG GTSYAQKFQGRVTMTRDTSTSTVYMELS SLRSEDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 91 DIQMTQSPSSLSASVGDRVTITCRASSS VSFLNWYQQKPGKAPKLLIYLTSSLQSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWRSNPPTFGGGTKVEIK hz103E9B3H2L2 VH 83 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWMGDINPNYG GTSYAQKFQGRVTMTRDTSTSTVYMELS SLRSEDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 92 DIQMTQSPSSLSASVGDRVTITCRASSS VSFLFWYQQKPGKAPKLLIYLTSSLASG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWRSNPPTFGGGTKVEIK hz103E9B3H2L3 VH 83 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWMGDINPNYG GTSYAQKFQGRVTMTRDTSTSTVYMELS SLRSEDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 93 DIQMTQSPSSLSASVGDRVTITCRASSS VSFMFWYQQKPGKAPKPLIYLTSSLASG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWRSNPPTFGGGTKVEIK hz103E9B3H2L4 VH 83 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWMGDINPNYG GTSYAQKFQGRVTMTRDTSTSTVYMELS SLRSEDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 94 DIQMTQSPSSLSASVGDRVTITCSASSS VSFMFWYQQKPGKAPKLLIYLTSNLASG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWRSNPPTFGGGTKVEIK hz103E9B3H2L5 VH 83 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWMGDINPNYG GTSYAQKFQGRVTMTRDTSTSTVYMELS SLRSEDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 95 DIQMTQSPSSLSASVGDRVTITCSASSS VSFMFWYQQKPGKAPKPLIYLTSNLASG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWRSNPPTFGGGTKVEIK hz103E9B3H2L6 VH 83 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWMGDINPNYG GTSYAQKFQGRVTMTRDTSTSTVYMELS SLRSEDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 96 DIQMTQSPSSLSASVGDRVTITCSASSS VSFMFWYQQKPGKAPKPWIYLTSNLASG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWRSNPPTFGGGTKVEIK hz103E9B3H3L1 VH 84 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWMGDINPNYG GTSYAQKFQGRVTLTVDTSTSTVYMELS SLRSEDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 91 DIQMTQSPSSLSASVGDRVTITCRASSS VSFLNWYQQKPGKAPKLLIYLTSSLQSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWRSNPPTFGGGTKVEIK hz103E9B3H3L2 VH 84 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWMGDINPNYG GTSYAQKFQGRVTLTVDTSTSTVYMELS SLRSEDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 92 DIQMTQSPSSLSASVGDRVTITCRASSS VSFLFWYQQKPGKAPKLLIYLTSSLASG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWRSNPPTFGGGTKVEIK hz103E9B3H3L3 VH 84 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWMGDINPNYG GTSYAQKFQGRVTLTVDTSTSTVYMELS SLRSEDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 93 DIQMTQSPSSLSASVGDRVTITCRASSS VSFMFWYQQKPGKAPKPLIYLTSSLASG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWRSNPPTFGGGTKVEIK hz103E9B3H3L4 VH 84 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWMGDINPNYG GTSYAQKFQGRVTLTVDTSTSTVYMELS SLRSEDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 94 DIQMTQSPSSLSASVGDRVTITCSASSS VSFMFWYQQKPGKAPKLLIYLTSNLASG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWRSNPPTFGGGTKVEIK hz103E9B3H3L5 VH 84 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWMGDINPNYG GTSYAQKFQGRVTLTVDTSTSTVYMELS SLRSEDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 95 DIQMTQSPSSLSASVGDRVTITCSASSS VSFMFWYQQKPGKAPKPLIYLTSNLASG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWRSNPPTFGGGTKVEIK hz103E9B3H3L6 VH 84 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWMGDINPNYG GTSYAQKFQGRVTLTVDTSTSTVYMELS SLRSEDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 96 DIQMTQSPSSLSASVGDRVTITCSASSS VSFMFWYQQKPGKAPKPWIYLTSNLASG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWRSNPPTFGGGTKVEIK hz103E9B3H4L1 VH 85 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWMGDINPNYG GTSYNQKFQGRVTLTVDTSTSTVYMELS SLRSEDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 91 DIQMTQSPSSLSASVGDRVTITCRASSS VSFLNWYQQKPGKAPKLLIYLTSSLQSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWRSNPPTFGGGTKVEIK hz103E9B3H4L2 VH 85 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWMGDINPNYG GTSYNQKFQGRVTLTVDTSTSTVYMELS SLRSEDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 92 DIQMTQSPSSLSASVGDRVTITCRASSS VSFLFWYQQKPGKAPKLLIYLTSSLASG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWRSNPPTFGGGTKVEIK hz103E9B3H4L3 VH 85 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWMGDINPNYG GTSYNQKFQGRVTLTVDTSTSTVYMELS SLRSEDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 93 DIQMTQSPSSLSASVGDRVTITCRASSS VSFMFWYQQKPGKAPKPLIYLTSSLASG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWRSNPPTFGGGTKVEIK hz103E9B3H4L4 VH 85 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWMGDINPNYG GTSYNQKFQGRVTLTVDTSTSTVYMELS SLRSEDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 94 DIQMTQSPSSLSASVGDRVTITCSASSS VSFMFWYQQKPGKAPKLLIYLTSNLASG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWRSNPPTFGGGTKVEIK hz103E9B3H4L5 VH 85 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWMGDINPNYG GTSYNQKFQGRVTLTVDTSTSTVYMELS SLRSEDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 95 DIQMTQSPSSLSASVGDRVTITCSASSS VSFMFWYQQKPGKAPKPLIYLTSNLASG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWRSNPPTFGGGTKVEIK hz103E9B3H4L6 VH 85 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWMGDINPNYG GTSYNQKFQGRVTLTVDTSTSTVYMELS SLRSEDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 96 DIQMTQSPSSLSASVGDRVTITCSASSS VSFMFWYQQKPGKAPKPWIYLTSNLASG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWRSNPPTFGGGTKVEIK hz103E9B3H5L1 VH 86 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWMGDINPNYG GTSYNEKFKDRVTMTTDTSTSTAYMELR SLRSDDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 91 DIQMTQSPSSLSASVGDRVTITCRASSS VSFLNWYQQKPGKAPKLLIYLTSSLQSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWRSNPPTFGGGTKVEIK hz103E9B3H5L2 VH 86 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWMGDINPNYG GTSYNEKFKDRVTMTTDTSTSTAYMELR SLRSDDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 92 DIQMTQSPSSLSASVGDRVTITCRASSS VSFLFWYQQKPGKAPKLLIYLTSSLASG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWRSNPPTFGGGTKVEIK hz103E9B3H5L3 VH 86 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWMGDINPNYG GTSYNEKFKDRVTMTTDTSTSTAYMELR SLRSDDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 93 DIQMTQSPSSLSASVGDRVTITCRASSS VSFMFWYQQKPGKAPKPLIYLTSSLASG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWRSNPPTFGGGTKVEIK hz103E9B3H5L4 VH 86 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWMGDINPNYG GTSYNEKFKDRVTMTTDTSTSTAYMELR SLRSDDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 94 DIQMTQSPSSLSASVGDRVTITCSASSS VSFMFWYQQKPGKAPKLLIYLTSNLASG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWRSNPPTFGGGTKVEIK hz103E9B3H5L5 VH 86 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWMGDINPNYG GTSYNEKFKDRVTMTTDTSTSTAYMELR SLRSDDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 95 DIQMTQSPSSLSASVGDRVTITCSASSS VSFMFWYQQKPGKAPKPLIYLTSNLASG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWRSNPPTFGGGTKVEIK hz103E9B3H5L6 VH 86 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWMGDINPNYG GTSYNEKFKDRVTMTTDTSTSTAYMELR SLRSDDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 96 DIQMTQSPSSLSASVGDRVTITCSASSS VSFMFWYQQKPGKAPKPWIYLTSNLASG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWRSNPPTFGGGTKVEIK hz103E9B3H6L1 VH 87 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWMGDINPNYG GTSYNEKFKDRATMTTDTSTSTAYMELR SLRSDDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 91 DIQMTQSPSSLSASVGDRVTITCRASSS VSFLNWYQQKPGKAPKLLIYLTSSLQSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWRSNPPTFGGGTKVEIK hz103E9B3H6L2 VH 87 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWMGDINPNYG GTSYNEKFKDRATMTTDTSTSTAYMELR SLRSDDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 92 DIQMTQSPSSLSASVGDRVTITCRASSS VSFLFWYQQKPGKAPKLLIYLTSSLASG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWRSNPPTFGGGTKVEIK hz103E9B3H6L3 VH 87 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWMGDINPNYG GTSYNEKFKDRATMTTDTSTSTAYMELR SLRSDDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 93 DIQMTQSPSSLSASVGDRVTITCRASSS VSFMFWYQQKPGKAPKPLIYLTSSLASG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWRSNPPTFGGGTKVEIK hz103E9B3H6L4 VH 87 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWMGDINPNYG GTSYNEKFKDRATMTTDTSTSTAYMELR SLRSDDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 94 DIQMTQSPSSLSASVGDRVTITCSASSS VSFMFWYQQKPGKAPKLLIYLTSNLASG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWRSNPPTFGGGTKVEIK hz103E9B3H6L5 VH 87 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWMGDINPNYG GTSYNEKFKDRATMTTDTSTSTAYMELR SLRSDDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 95 DIQMTQSPSSLSASVGDRVTITCSASSS VSFMFWYQQKPGKAPKPLIYLTSNLASG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWRSNPPTFGGGTKVEIK hz103E9B3H6L6 VH 87 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWMGDINPNYG GTSYNEKFKDRATMTTDTSTSTAYMELR SLRSDDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 96 DIQMTQSPSSLSASVGDRVTITCSASSS VSFMFWYQQKPGKAPKPWIYLTSNLASG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWRSNPPTFGGGTKVEIK hz103E9B3H7L1 VH 88 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWIGDINPNYG GTSYNEKFKDRATLTTDTSTSTAYMELR SLRSDDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 91 DIQMTQSPSSLSASVGDRVTITCRASSS VSFLNWYQQKPGKAPKLLIYLTSSLQSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWRSNPPTFGGGTKVEIK hz103E9B3H7L2 VH 88 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWIGDINPNYG GTSYNEKFKDRATLTTDTSTSTAYMELR SLRSDDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 92 DIQMTQSPSSLSASVGDRVTITCRASSS VSFLFWYQQKPGKAPKLLIYLTSSLASG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWRSNPPTFGGGTKVEIK hz103E9B3H7L3 VH 88 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWIGDINPNYG GTSYNEKFKDRATLTTDTSTSTAYMELR SLRSDDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 93 DIQMTQSPSSLSASVGDRVTITCRASSS VSFMFWYQQKPGKAPKPLIYLTSSLASG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWRSNPPTFGGGTKVEIK hz103E9B3H7L4 VH 88 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWIGDINPNYG GTSYNEKFKDRATLTTDTSTSTAYMELR SLRSDDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 94 DIQMTQSPSSLSASVGDRVTITCSASSS VSFMFWYQQKPGKAPKLLIYLTSNLASG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWRSNPPTFGGGTKVEIK hz103E9B3H7L5 VH 88 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWIGDINPNYG GTSYNEKFKDRATLTTDTSTSTAYMELR SLRSDDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 95 DIQMTQSPSSLSASVGDRVTITCSASSS VSFMFWYQQKPGKAPKPLIYLTSNLASG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWRSNPPTFGGGTKVEIK hz103E9B3H7L6 VH 88 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWIGDINPNYG GTSYNEKFKDRATLTTDTSTSTAYMELR SLRSDDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 96 DIQMTQSPSSLSASVGDRVTITCSASSS VSFMFWYQQKPGKAPKPWIYLTSNLASG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWRSNPPTFGGGTKVEIK hz103E9B3H8L1 VH 89 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWIGDINPNYG GTSYNEKFKDRATLTTDTSTSTAYMELR SLRSDDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 91 DIQMTQSPSSLASVGDRVTITCRASSSV SFLNWYQQKPGKAPKLLIYLTSSLQSGV PSRFSGSGSGTDFTLTISSLQPEDFATY YCQQWRSNPPTFGGGTKVEIK hz103E9B3H8L2 VH 89 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWIGDINPNYG GTSYNEKFKDRATLTVDTSTSTAYMELR SLRSDDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 92 DIQMTQSPSSLSASVGDRVTITCRASSS VSFLFWYQQKPGKAPKLLIYLTSSLASG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWRSNPPTFGGGTKVEIK hz103E9B3H8L3 VH 89 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWIGDINPNYG GTSYNEKFKDRATLTVDTSTSTAYMELR SLRSDDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 93 DIQMTQSPSSLSASVGDRVTITCRASSS VSFMFWYQQKPGKAPKPLIYLTSSLASG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWRSNPPTFGGGTKVEIK hz103E9B3H8L4 VH 89 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWIGDINPNYG GTSYNEKFKDRATLTVDTSTSTAYMELR SLRSDDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 94 DIQMTQSPSSLSASVGDRVTITCSASSS VSFMFWYQQKPGKAPKLLIYLTSNLASG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWRSNPPTFGGGTKVEIK hz103E9B3H8L5 VH 89 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWIGDINPNYG GTSYNEKFKDRATLTVDTSTSTAYMELR SLRSDDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 95 DIQMTQSPSSLSASVGDRVTITCSASSS VSFMFWYQQKPGKAPKPLIYLTSNLASG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWRSNPPTFGGGTKVEIK hz103E9B3H8L6 VH 89 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWIGDINPNYG GTSYNEKFKDRATLTVDTSTSTAYMELR SLRSDDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 96 DIQMTQSPSSLSASVGDRVTITCSASSS VSFMFWYQQKPGKAPKPWIYLTSNLASG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWRSNPPTFGGGTKVEIK hz103E9B3H9L1 VH 90 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWIGDINPNYG GTSYNEKFKDRATLTVDKSTSTAYMELR SLRSDDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 91 DIQMTQSPSSLSASVGDRVTITCRASSS VSFLNWYQQKPGKAPKLLIYLTSSLQSG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWRSNPPTFGGGTKVEIK hz103E9B3H9L2 VH 90 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWIGDINPNYG GTSYNEKFKDRATLTVDKSTSTAYMELR SLRSDDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 92 DIQMTQSPSSLSASVGDRVTITCRASSS VSFLFWYQQKPGKAPKLLIYLTSSLASG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWRSNPPTFGGGTKVEIK hz103E9B3H9L3 VH 90 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWIGDINPNYG GTSYNEKFKDRATLTVDKSTSTAYMELR SLRSDDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 93 DIQMTQSPSSLSASVGDRVTITCRASSS VSFMFWYQQKPGKAPKPLIYLTSSLASG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWRSNPPTFGGGTKVEIK hz103E9B3H9L4 VH 90 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWIGDINPNYG GTSYNEKFKDRATLTVDKSTSTAYMELR SLRSDDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 94 DIQMTQSPSSLSASVGDRVTITCSASSS VSFMFWYQQKPGKAPKLLIYLTSNLASG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWRSNPPTFGGGTKVEIK hz103E9B3H9L5 VH 90 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWIGDINPNYG GTSYNEKFKDRATLTVDKSTSTAYMELR SLRSDDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 95 DIQMTQSPSSLSASVGDRVTITCSASSS VSFMFWYQQKPGKAPKPLIYLTSNLASG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWRSNPPTFGGGTKVEIK hz103E9B3H9L6 VH 90 EVQLVQSGAEVKKPGASVKVSCKASGYT FTSYTMHWVRQAPGQGLEWIGDINPNYG GTSYNEKFKDRATLTVDKSTSTAYMELR SLRSDDTAVYYCAREGATGTWYFDVWGQ GTTVTVSS VL 96 DIQMTQSPSSLSASVGDRVTITCSASSS VSFMFWYQQKPGKAPKPWIYLTSNLASG VPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQWRSNPPTFGGGTKVEIK